Document:

Exhibit 10.13

 

SERVICES AGREEMENT

 

This Services Agreement
(this “Agreement”) is made and entered into as of July 15, 2020, (the “Effective Date”),
by and between Worldwide Clinical Trials, Inc., with offices at 3800 Paramount Parkway, Suite 400, 27560, Morrisville, NC, United
States, (together with its Affiliates, “Worldwide) and Neurotrope Bioscience, Inc., with offices at 1185 Avenue of
the Americas, 3rd Floor, New York, NY 10036 (“Sponsor”). Worldwide and Sponsor are sometimes individually referred
to herein as a “Party” and collectively as the “Parties”.

 

For purposes of this
Agreement, “Affiliates” means any entity that controls, is controlled by or is under common control with, that
Party. “Control” means the possession, directly or indirectly, of at least 50% of the share capital or voting
rights or of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership
of voting securities, by contract or otherwise.

 

WHEREAS, Sponsor is
engaged in the research and development of pharmaceutical products;

 

WHEREAS, Worldwide
is engaged in providing services to pharmaceutical manufacturers in support of their clinical research and product development
activities;

 

WHEREAS, Worldwide
and Sponsor desire that Worldwide provide certain services with respect to Sponsor’s clinical study, NTRP-101-204 entitled
 “A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin
in the Treatment of Moderately Severe Alzheimer’s Disease Subjects Not Receiving Memantine Treatment” (the "Study")
for the study of Sponsor’s drug Bryostatin 1 ("Study Drug"); and

 

WHEREAS, Sponsor and
Worldwide desire to enter into this Agreement in order to set forth definitively their respective rights and obligations with respect
to the conduct of the Study.

 

NOW THEREFORE, in consideration
of the premises and the mutual promises and undertakings herein contained, the receipt and sufficiency of which is hereby acknowledged,
the Parties agree as follows:

 

1.0       
SERVICES

  

Worldwide, itself or through one of its
Affiliates (if applicable) hereby agrees to perform the services (the “Services”) in accordance with the terms
of the scope of Services attached hereto as Exhibit A, incorporated herein by reference (the “Scope of Services”),
and this Agreement.

 

1.1       Performance

 

Worldwide shall perform the Services and
shall use its commercially reasonable efforts to complete the Services within the estimated time frame as set forth in the timeline
attached hereto as Exhibit B and incorporated herein by reference (“Timeline”). Such time estimate assumes,
however, the full cooperation of Sponsor, Regulatory Authorities, Ethics Committees and investigators and other third parties not
under Worldwide’s control, and shall be subject to adjustment (including costs) if the work for the Services is delayed due
to circumstances outside the reasonable control of Worldwide, including, but not limited to:

 

    Page 1 of 47

     

    

 

		·	failure of Sponsor to deliver clinical
supplies in due time, provided such failure is the actual cause of the delay; 
	 	 	 
		·	amendments to previously agreed upon protocols,
procedures or documents required for the Services at the request of Sponsor or Sponsor’s (or its advisors’); 
	 	 	 
		·	significant delays in pre-Study meetings
or in other tasks to be performed by Worldwide caused by Sponsor;
	 	 	 
		·	delays in obtaining or subsequent withdrawal
of regulatory or ethical review approvals concerning the Services; 
	 	 	 
		·	death or disability of any investigator
or other research specialist on the Study; 
	 	 	 
		·	higher ratio of drop-outs among trial
subjects than anticipated in this Agreement; 
	 	 	 
		·	lower enrollment rates than expected and
agreed to by Worldwide and Sponsor; or
	 	 	 
		·	unforeseen changes in the relevant medical
practice.

 

1.2       Compliance
with Laws/Agreements

 

Worldwide shall perform Services under
this Agreement in accordance with the terms of this Agreement, the Protocol for the Study, the Sponsor approved standard operating
procedures for the Study (the “Standard Operating Procedures”), the current Guidelines for Good Clinical Practice
promulgated by the FDA ("GCP Guidelines"), the Declaration of Helsinki of the 41st World Medical Assembly, South
Africa 1996 as amended, and all other applicable laws and regulations, including the following as applicable, 21 CFR Part 11, 312,
50, 54, 56, the Health Information Portability and Accountability Act of 1996 and all regulations and official guidelines promulgated
thereunder and the Health Information Technology for Economic and Clinical Health Act (the “Applicable Laws”).

 

The Parties and their respective owners,
officers, directors, employees or agents have not and shall not pay, give, offer or promise to pay or give, or authorize the payment,
directly or indirectly, of any money or anything of value to any foreign government official or employee (including employees of
state-owned institutions), for the purpose of (i) influencing any act or decision of such official or of such government, (ii)
inducing that person to do or omit doing any act in violation of his or her lawful duty, (iii) securing an improper advantage,
or (iv) influencing such official to use his influence with the government to effect or influence the decision of such government,
in order to assist Sponsor or Worldwide in obtaining or retaining business for or with or directing business to any person.

 

Each Party agrees to comply with all applicable
anticorruption laws, rules and regulations. The Parties agree to reasonably cooperate with each other’s diligence efforts
in order to satisfy each Party’s obligations under the United States Foreign Corrupt Practices Act, as amended (“FCPA”),
the UK Bribery Act and any implementing legislation under the OECD Convention Against Bribery of Foreign Government Officials in
International Business Transactions.

 

1.3        Transfer
of Obligations

 

Pursuant to Title 21 CFR Part 312.52, Sponsor
hereby transfers to Worldwide all of the obligations identified in Exhibit A attached hereto and incorporated by reference herein.
Notwithstanding the foregoing, Sponsor will retain the ultimate authority and control over and responsibility for the Study. The
Parties acknowledge and agree that Sponsor shall at all times be deemed to be the “sponsor” of the Study pursuant to
the terms of the Federal Food, Drug and Cosmetic Act, as from time to time amended, and the regulations of the U.S. Food and Drug
Administration (“FDA”), as promulgated in Title 21 of U.S. Code of Federal Regulations.

 

    Page 2 of 47

     

    

 

1.4       Changes

 

The Parties may make changes in or additions
to the Scope of Services, provided, however, that, subject to the terms of this Section 1.4, no such changes or additions shall
be implemented prior to the execution by the Parties of a change order (a “Change Order”), the form of which
is attached hereto and incorporated herein as Exhibit E. The Change Order shall include detailed information on the changes to
the Scope of Services and any associated changes to the Timeline, Budget and/or payment schedule. Sponsor acknowledges that Worldwide
is not obligated to perform any out-of-scope work described in a Change Order until the Change Order is signed by both Parties.
Provided, however, in the event that Worldwide provides additional Services or expends additional resources, at Sponsor’s
written request and in strict accordance with Sponsor’s written requirements, in the absence of a Change Order, Sponsor will
compensate and/or reimburse Worldwide for all pre-approved reasonable and necessary fees and reasonable and necessary out-of-pocket
costs actually incurred. For any Change Order that affects the scope of the regulatory obligations that have been transferred to
Worldwide, Worldwide and Sponsor shall execute a corresponding amendment to Exhibit A. Sponsor shall file such amendment where
appropriate, or as required by applicable law.

 

2.0       WORK
PRODUCT

 

During the term of this Agreement, Worldwide
shall maintain all materials and all other data or documents included in the Trial Master File obtained or generated by Worldwide
in the course of providing the relevant Services in accordance with Worldwide’s standard operating procedures, including
all computerized records and files (“Work Product”), in a secure area reasonably protected from fire, theft
and destruction with duplicate copies retained with the same care as the original Work Product. All Work Product shall be the Confidential
Information and the exclusive property of Sponsor. At the expiration or termination of this Agreement, and subject to satisfaction
of the Parties’ obligations thereunder, Sponsor shall provide Worldwide with written instructions as to the disposition of
the Work Product created under this Agreement. Such written instructions will provide that Worldwide (a) deliver the Work Product,
in the form in which Worldwide currently holds them, to a designated Sponsor location or to such other entity or at such other
address as Sponsor may specify, (b) retain the materials for the period of time specified in this Agreement, or (c) destroy all
such materials except for those which Worldwide is required by law or regulation to store or maintain. Upon expiration or termination
of this Agreement, any storage, destruction or shipping costs or services relating to such disposition of the Work Product will
be billed by Worldwide to Sponsor as Pass-through Expenses (as defined below) in accordance with the terms of this Agreement. Notwithstanding
the foregoing, Worldwide may retain one electronic archival backup copy of such Work Product in accordance with Worldwide’s
Data Retention Policy, subject to its ongoing obligation to maintain the confidentiality of such materials.

 

3.0        PAYMENT
AND COMPENSATION

 

The Parties agree that the fees and other
reimbursements that Worldwide will receive for performing the Services hereunder are subject to the following terms and conditions.

 

3.1        Compensation
for Services

 

This Agreement includes a budget for
the Services (the, “Budget”) to be performed by Worldwide, which is attached hereto as Exhibit C, and is
incorporated herein by reference. Sponsor shall pay to Worldwide such amounts as set forth and more fully described in the
Budget until such time as Worldwide and Sponsor agree that the Sponsor’s monetary obligations to Worldwide are fully
satisfied. Worldwide agrees that it shall not incur any cost or expense in excess of the amounts set forth in the Budget for
any item, without the prior written approval of Sponsor (in accordance with Section 1.4). Worldwide will use its commercially
reasonable efforts to control and limit the costs and expenses, including Pass-through Expenses (as defined below),
associated with this Agreement and to obtain and pass along to Sponsor all available discounts and allowances.

 

    Page 3 of 47

     

    

 

3.2       Pass-through
Expenses

 

Sponsor will reimburse Worldwide for travel
and other reasonable and necessary out-of-pocket expenses, exclusive of grant payments (described below), actually incurred by
Worldwide as agreed to by Sponsor and identified in the Budget or otherwise pre-approved in writing by the Sponsor, which Worldwide
will invoice to Sponsor without mark-up (“Pass-through Expenses”). All reimbursement of Pass-through Expenses
hereunder must be supported by receipts provided by Worldwide. Pass-through Expenses may include, but shall not be limited to lodging,
travel, third party vendor costs, and other reasonable and necessary costs.

 

In order to facilitate payment of invoices
for Worldwide’s pre-approved travel expenses incurred during the performance of Services, Worldwide will submit to Sponsor
a report containing at least the following details: (i) photocopies of receipts greater than Two Hundred Fifty ($250.00) USD for
Study-related travel expenses, including lodging, air travel, ground transportation, meals and other miscellaneous expenses, such
as overnight courier charges and photocopying, (ii) date and travel destination, (iii) employee name, and (iv) purpose of trip/expense.
In addition to copies of all receipts over Two Hundred Fifty ($250.00) USD, Sponsor shall have the right to obtain additional backing
documentation for any line item which requires further clarifications. Such requests shall be made in good faith and where there
is a specific concern with the line item(s) in question. All expenses, discounts, rebates and allowances obtained under Section
3.2 will be passed through and properly reflected in invoices to Sponsor and shall be without mark up. Worldwide will use economy
class airfare for all domestic flights and all international flights which are less than eight (8) hours in flight duration, and
business class airfare for all international fights which are eight (8) hours or more in flight duration. For the avoidance of
doubt, calculations of flight duration should not include layover time between flights.

 

3.3       Invoices;

 

Worldwide shall submit a reasonably detailed
invoice by email to Sponsor (rweinstein@neurotropebioscience.com) on a monthly basis in accordance with the Payment Schedule with
appropriate supporting documentation, including those set forth in Section 3.2.

 

3.4       Payment
Terms

 

Sponsor agrees to pay for Services and
Pass-through Expenses in accordance with the Payment Schedule, the (“Payment Schedule”) attached hereto as Exhibit
D and incorporated herein by reference. Sponsor will pay for all Services, Pass-through Expenses and other invoiced items within
forty five (45) days of receipt of invoice. All payments will be made in the currency noted in the Payment Schedule. All fees for
Services and Pass-through Expenses under this Agreement are stated exclusive of any local, state, federal or foreign sales and
use taxes, VAT, if any, as any such taxes shall be paid by Sponsor. If such taxes are applicable under local regulations, Worldwide
will add these taxes to the invoices at the relevant rate. For the avoidance of doubt, the requirements of this provision shall
not apply to any employment-related taxes, income taxes, duties, or withholding and shall only apply to taxes applicable to the
Services.

 

Payments shall be made by Sponsor via wire
transfer of immediately available funds to Worldwide’s account set forth below:

 

	 	Account Holder:	Worldwide Clinical Trials, Inc.
	 	Bank Name:	HSBC Bank USA, NA

 

    Page 4 of 47

     

    

 

	 	Bank Address: 	445 North Bedford Dr.
	 	 	Beverly Hills, CA 90210
	 	ABA Routing No.: 	021001088
	 	Bank Account No.: 	167-74758-4
	 	Swift Code:	MRMDUS33
	 	Taxpayer ID#: 	26-0902850

 

3.5       Project
Delays

 

In the event Sponsor delays, suspends or
places a hold on the Study for any reason, Sponsor shall promptly provide Worldwide with written notice of such delay, hold or
suspension, and Sponsor and Worldwide will, within 30 days of such notice, agree on appropriate revisions to this Agreement and
each Party will complete its respective duties and obligations as described in any resulting Change Order. During the period following
Worldwide’s receipt of Sponsor’s notice of delay, hold or suspension, if Sponsor desires Worldwide to continue the
assignment of certain Worldwide Study personnel to the Study, in addition to any other payments due to Worldwide hereunder, Sponsor
agrees that it shall pay for such special personnel fees associated with such continued assignment at a negotiated rate, such negotiated
rate to be agreed upon by the Parties prior to commencement of the delay, as evidenced by a Change Order. Said personnel fees shall
be invoiced by Worldwide on a monthly basis and shall be due and payable by Sponsor within forty-five (45) days of Sponsor’s
receipt of Worldwide’s invoice. If Sponsor does not wish to retain certain Worldwide Study personnel for the duration of
the delay or on hold period, Worldwide shall have the right to reallocate any and all such staff after such thirty (30) calendar
day period. If the delay or on-hold period continues for ninety (90) days either Party may, by provision of written notice, terminate
this Agreement without penalty.

 

3.6       Currency
Management

 

All invoices and amounts to be paid under
this Agreement shall be in US currency.

 

3.7       Disputed
Invoices

 

In the event Sponsor disputes one or more
items in an invoice, Sponsor will notify Worldwide in writing within thirty (30) business days of receipt of the invoice and such
notice shall contain a reasonably detailed description of the item(s) being disputed and the basis therefor. Worldwide will respond
to Sponsor within ten (10) business days of receipt of the notification. This written communication pattern will continue until
Worldwide has provided Sponsor with sufficient justification for the disputed item(s) or until the Parties agree to a resolution
of the disputed amount. Sponsor shall pay the undisputed portion of the invoice within forty-five (45) days of receipt of invoice
and shall use its reasonable efforts to pay the disputed amount within fifteen (15) days of resolution of the dispute pursuant
to Section 17.12. In the event the Parties are unable to reach a satisfactory resolution within sixty (60) days of the original
invoice, either Party may pursue alternative remedies in accordance with this Agreement.

 

4.0       THIRD
PARTY AGREEMENTS

 

Worldwide may contract with various
third parties to perform part of the Services, with the prior written consent of the Sponsor, provided that (i) the
subcontractor agrees in writing to be bound by terms consistent with this Agreement, including without limitation, regarding
maintaining the confidentiality of proprietary information, and regarding ownership of intellectual property in connection
with the Services, assignment to Sponsor of any intellectual property in connection with the Services; (ii) Worldwide shall
use its best efforts to ensure that any subcontractor has the capability to perform the subcontracted services to the
standards required under this Agreement and in compliance with Applicable Laws, (iii) Worldwide shall remain primarily
responsible to Sponsor for the performance of such subcontracted Services, and (iv) any subcontracting shall not relieve
Worldwide of its obligations hereunder and Worldwide hereby agrees to manage the performance of any permitted
subcontractor.

 

    Page 5 of 47

     

    

 

For purposes of this Agreement, subcontractors
do not include third party vendors providing ancillary services on the Study, provided that Worldwide’s agreement with any
such third-party vendor includes a provision making Sponsor an intended third-party beneficiary of the agreement with a right to
enforce Worldwide’s rights under the agreement. Liability of Worldwide to Sponsor with respect to such third-party vendors
shall be limited to the extent Worldwide is negligent in the performance of its obligations under this Agreement; however, Worldwide
shall provide to Sponsor any amounts that Worldwide may recover from such third party vendors as a result of any error or service
failure on the part of such vendors in connection with Services under this Agreement.

 

If Sponsor requests that Worldwide use
a particular third party and Worldwide does not wish to contract with that third party based upon commercially reasonable reasons
(such as the inability to agree with such provider upon mutually acceptable terms or a negative assessment of such provider’s
performance or abilities), then Sponsor shall contract directly with such provider (a “Sponsor Designated Vendor”)
and, unless otherwise agreed in writing, Worldwide will have no responsibility for the selection, instruction or supervision of
such Sponsor Designated Vendor.

 

4.1       Institutions/Investigators

 

Worldwide’s Services under this Agreement
may include identifying potential medical institutions (“Institutions”) or clinical investigators (“Investigators”)
and/or negotiating, executing and/or administering contracts with such parties which will govern their participation in the Study
(“Clinical Trial Agreements”). If, pursuant to the Scope of Services, Sponsor delegates to Worldwide the responsibility
for negotiating and/or executing Clinical Trial Agreements, the following provisions will apply:

 

		(a)	Sponsor may provide Worldwide with a list of suggested Institutions and/or Investigators to be
recruited by Worldwide for a Study. Worldwide shall notify Sponsor in writing as to any listed Institution/Investigator with which
Worldwide does not wish to contract.

 

		(b)	Selection of all Institutions or Investigators will be subject to approval by Sponsor prior to
initiation of any Study-related activities involving that Institution/Investigator or the start of any negotiations with such Institution/Investigator.

 

		(c)	Each Clinical Trial Agreement shall be consistent with this Agreement. The Clinical Trial Agreement
used with each Institution and Investigator will be in a form approved in advance by Sponsor. Any
material changes to the form Clinical Trial Agreement shall be replaced with fall-back language that has been pre-approved by Sponsor.
If outside of the fall-back language, the change shall require the prior written approval of the Sponsor.

 

	 	(d)	In the event that local law prohibits Sponsor from being a party to a Clinical Trial Agreement, Sponsor (a) shall have the right
to approve the Clinical Trial Agreement template; (b) shall be a named third-party beneficiary to each Clinical Trial Agreement
if possible; and, (c) shall have the right but no obligation to approve all finalized Clinical Trial Agreements prior to execution
by Worldwide.

 

    Page 6 of 47

     

    

 

		(e)	If an Institution/Investigator requests indemnification from Sponsor, standard indemnification
language, generated by the Sponsor, will be provided to the Institution/Investigator. If the Institution/Investigator requests
changes to the standard language, Sponsor will negotiate
with the Institution/Investigator, if agreed, Sponsor will issue a letter of indemnification directly to the Institution/Investigator.
Sponsor acknowledges that Worldwide shall have no indemnification obligation to any Institution/Investigator relative to the Study
Drug or the applicable Study protocol. In addition, Worldwide shall not be deemed to have failed to perform under this Agreement
in the event an Institution/Investigator declines participation in a Study as a result of Sponsor’s refusal to indemnify
such Institution/Investigator.

  

		(f)	The Sponsor may elect that grant payments to Institutions/Investigators be administered on its
behalf by Worldwide, acting solely as payment agent unless otherwise agreed to by Worldwide in writing. Worldwide shall distribute
all payments to Institutions/Investigators according to the provisions of the applicable Clinical Trial Agreement and this Agreement.
Sponsor acknowledges and agrees that Worldwide will manage all administration of payments or other obligations to Investigators/Institutions
for Services rendered in connection with relevant Studies solely out of funds provided to Worldwide from Sponsor for this specific
purpose. Furthermore, Sponsor acknowledges and agrees that Worldwide intends to maintain a cash neutral policy with regard to Institutions/Investigators
payments. In the event Worldwide or the Institutions/Investigators incur bank fees with respect to the remittance of these grant
payments, such fees will be borne by Sponsor. All payments to Institutions/Investigators and any associated bank fees will be made
by Worldwide solely from the funds that have been specifically provided by Sponsor to Worldwide for this purpose and not from Worldwide
funds. Worldwide will not be liable for payments not made on a timely basis to any Institution/Investigator as a result of Sponsor’s
failure to provide, in advance, sufficient funds for such payments.

 

The Parties acknowledge and agree that,
for the purposes of this Agreement, Institutions/Investigators shall not be considered as employees, agents or subcontractors of
Worldwide and that Investigators will be required to exercise their own independent medical judgement. Worldwide’s responsibilities
with respect to Institutions/Investigators shall be limited to those specifically set forth in this Agreement.

 

5.0       CONFIDENTIAL
INFORMATION

 

The Parties acknowledge and agree that
in the course of performing Services hereunder, either Party may be exposed to or be given confidential or proprietary information
of the other Party (“Confidential Information”). The Parties agree to hold all Confidential Information in secrecy
for a period of ten (10) years from the effective date of the expiration or earlier termination of this Agreement and shall disclose
Confidential Information to third parties only on a need-to-know basis. Without limiting the generality of the foregoing, Confidential
Information shall include, without limitation, financial information, protocols, brochures, formulations, research and development
programs, methodology, testing techniques, analytical test method, test samples and prototypes, information gathered or viewed
during a site visit, audit or inspection of a Party, analyses, software, source codes and technological or other know-how. Confidential
Information shall be deemed to be all such information given by the disclosing party to the receiving party except for information
which is (i) publicly available or later becomes publicly available through no fault of the receiving party; (ii) obtained by the
receiving party from a third party entitled to disclose it; (iii) already in possession of the receiving party as indicated in
its written records; (iv) independently developed by the receiving party without use of the Confidential Information; or (v) required
by any law, rule, regulation, order, decision, decree, or subpoena or other judicial, administrative, or legal process to be disclosed.

 

    Page 7 of 47

     

    

 

Both Parties shall ensure that all of its
officers, employees, consultants, agents, investigators or contractors who receive such Confidential Information understand and
shall be bound by the confidentiality provisions of this Agreement.

  

Unless otherwise agreed in writing, within
thirty (30) days after the termination of the Agreement or the written request by the disclosing party, the receiving party shall
return to the disclosing party all Confidential Information in documentary or permanent form including any and all copies thereof,
except for one archival copy that the receiving party can keep for its records (which may be electronic). The Parties agree that
each party is and shall remain the exclusive owner of its own Confidential Information and all patent, copyright, trade secret
and other intellectual property rights therein unless and until a further agreement is executed.

 

The Parties acknowledge that any violation
of the terms of this Section 5.0 may result in irreparable injury and damage to disclosing party that is not adequately compensable
in money damages, and for which disclosing party may have no adequate remedy at law. Accordingly, the receiving party agrees that
the disclosing party shall be entitled to seek (without waiving any additional rights or remedies, including monetary damages,
otherwise available to the disclosing party at law, in equity, or by statute) preliminary and permanent injunctive relief in the
event of a breach or intended or threatened breach by the receiving party.

 

6.0       OWNERSHIP
OF DATA AND INTELLECTUAL PROPERTY

 

Any invention, discovery, processes, know-how,
trade secrets, data, copyrights, trademarks, improvements, or any other intellectual property right related to Sponsor’s
products or technology, including the Study Drug, the Protocol, Sponsor’s Confidential Information, which is conceived or
reduced to practice as a result of the performance of the Services hereunder (the “Inventions”) shall become
Sponsor property and shall be used by Sponsor as Sponsor deems appropriate. Worldwide agrees to, and shall contractually require
and use reasonable efforts to cause Institutions and Investigators to execute and have executed assignments of the Inventions to
Sponsor, along with other documents that be necessary or helpful to Sponsor in filing patent applications, or which may relate
to any litigation or interference and/or controversy in connection therewith. The entire control, prosecution, and conduct of any
patent application filed by Sponsor shall be outside the jurisdiction of and without expense to Worldwide and its officers, employees,
representatives and agents. Worldwide acknowledges that Sponsor has the exclusive right to file patent applications in connection
with the Inventions. Worldwide warrants that neither it, nor its employees, agents and representatives, will prevent Sponsor from
filing patent applications for, or from applying the results of the research carried out for Sponsor hereunder.

 

All reports, data, technical information,
original works of authorship and all other information, furnished by or on behalf of Sponsor, or created specifically for Sponsor
as a deliverable under a this Agreement, shall be the sole property of Sponsor. Nothing under this Section or any other Section
of this Agreement shall be construed as (i) granting to any Party any rights under any patent, copyright or other intellectual
property right of the other Party (ii) granting to any Party any rights in or to the Confidential Information of the other Party
other than the limited right to use such Confidential Information solely for the purposes expressly permitted by Section 5.0 of
this Agreement.

 

    Page 8 of 47

     

    

 

Sponsor acknowledges that Worldwide
possesses certain computer programs, applications, algorithms, databases, methods, techniques, processes and other materials
and ideas independently developed by Worldwide which do not rely upon, reference, or inextricably incorporate Sponsor
Confidential Information or Study Drug and which relate to Worldwide’s business or operations (“Worldwide
Works”). All Worldwide Works, and all revisions, improvements and enhancements thereto, are the exclusive property
of Worldwide or its licensors. Sponsor agrees that any improvements, alterations or enhancements to the Worldwide Works
during the term of this Agreement or the Study shall be the sole property of Worldwide. Subject to Section 5.0 hereof, in no
event shall Worldwide be precluded from use of its general knowledge, skills and experience, and any of its ideas, concepts,
know-how and techniques used or developed by it in the course of providing Services under this Agreement. Worldwide
represents and warrants that it is entitled to deliver Worldwide Works where the same is delivered as part of the Services
hereunder for Sponsor and its Affiliates’ use, and Worldwide further represents and warrants that use by Sponsor and
its Affiliates’ of any such Worldwide Works is properly authorized and will not constitute an infringement or other
violation of any rights of any third party.

 

7.0       TERM
AND TERMINATION

 

7.1        Term

 

Unless earlier terminated according to
Sections 7.2-7.5 below, this Agreement will remain in effect from the date first written above until Worldwide has completed performance
of all Services (including delivery of all deliverables) and Worldwide has received from Sponsor all of the payments due hereunder.

 

7.2       Termination
for Material Breach 

 

In the event that either Party commits
a material breach in any of the terms or conditions of this Agreement, and that Party fails to cure the breach within thirty (30)
days after receipt of notice of the default or breach from the other Party, the Party giving notice may, at its option, immediately
terminate this Agreement at the end of the 30-day period. For the avoidance of doubt, non-payment of undisputed invoices by Sponsor
or non-payment by Worldwide to Institutions/Investigators under Section 4.1(f) shall automatically be deemed a material breach.

 

7.3       Termination
by Sponsor without Cause

 

Sponsor shall have the right to terminate
this Agreement (for other than breach by Worldwide) at any time by giving appropriate written notice at least sixty (60) days prior
to the desired termination date.

 

7.4       Termination
for Other Reasons

 

Sponsor shall have the right to terminate
this Agreement due to patient safety at any time by giving appropriate written notice. Either Party shall have the right to terminate
this Agreement at any time upon receipt of written notice to the other Party, if the other Party shall be adjudicated insolvent
or shall petition for or consent to any relief under any insolvency, re-organization, receivership, liquidation, compromise, or
any moratorium statute, whether now or hereafter in effect, or shall make an assignment for the benefit of its creditors, or shall
petition for the appointment of a receiver, liquidator, trustee, or custodian for all or a substantial part of its assets, or if
a receiver, liquidator, trustee or custodian is appointed for all or a substantial part of its assets and is not discharged within
thirty (30) days after the date of such appointment. In the event that any of the above events occur, that Party shall immediately
notify the other, in writing, of its occurrence.

 

    Page 9 of 47

     

    

 

7.5       Termination
Procedures

 

Upon termination of this Agreement,
the Parties will reasonably cooperate with each other to provide for an orderly cessation of Worldwide’s Services.
Worldwide shall use its commercially reasonable efforts to minimize costs associated with the cessation of the Services. In
the event Sponsor terminates only part of the Services, the Parties will cooperate in good faith to enter into a Change Order
amending the terms of this Agreement accordingly. In the event the Agreement or any of the Services is terminated, Worldwide
will be entitled to receive payment for Services
performed (based on units completed) and pre-approved expenses actually incurred or irrevocably committed to third parties
(excluding salary and overhead) up to the effective date of termination. In addition, Sponsor shall pay all reasonable fees
and expenses incurred by Worldwide that are necessary or reasonably required in connection with the orderly cessation of the
Services. If a Study or the Agreement is cancelled or terminated before the Services have been performed completely,
Worldwide shall refund to Sponsor any funds advanced to Worldwide for fees and costs not yet incurred or due to the extent
that the payments for the liabilities associated with such fees or costs can reasonably be avoided in whole or in part. 

 

8.0       DEBARMENT
CERTIFICATION

 

Worldwide and its Affiliates represent
and certify that neither they, nor any of their respective employees or Study personnel have ever been (a) debarred or voluntarily
excluded or convicted of a crime for which a person can be debarred under Section 306 of the Federal Food, Drug, and Cosmetic Act,
21 U.S.C. §335a(a) , as amended, or any equivalent local law, regulation or guidelines thereof, in any country in which any
portion of the Study is conducted (“§335a”); nor (b) threatened to be debarred or voluntarily excluded or indicted
for a crime or otherwise engaged in conduct for which a person can be debarred under § 335a, or subject to any governmental
sanction that would prevent the rendering of Services hereunder in any jurisdiction in which the Study is to be conducted, nor
(c) excluded from participation in any federally-funded health-care program. Worldwide agrees that it shall notify Sponsor in writing
within 2 days in the event of any debarment, voluntary exclusion, conviction, threat, indictment or exclusion prohibited by this
Section occurring during the Term of this Agreement and will suspend all activity of such individual immediately upon notification
of investigation or debarment.

 

Worldwide represents and certifies that
it has not and will not knowingly use in any capacity the services of any individual, corporation, partnership, or association
which has been (a) debarred or voluntarily excluded or convicted of a crime for which a person can be debarred under § 335a;
(b) threatened to be debarred or voluntarily excluded or indicted for a crime or otherwise engaged in conduct for which a person
can be debarred under § 335a, or subject to any governmental sanction that would prevent the rendering of Services hereunder
in any jurisdiction in which the Study is to be conducted or (c) excluded from participation in any federally funded health care
program.

 

		9.0	RECORDS, AUDITS AND INSPECTIONS

  

		9.1	Records

 

Worldwide shall keep full and accurate
records and accounts of all its activities in connection with this Agreement, including reasonable substantiation of all Services
provided, expenses incurred. Additionally, Worldwide shall maintain a system of internal controls sufficient to provide reasonable
assurance that all transactions related to this Agreement are executed and are properly recorded in Worldwide’s books and
records. All records relating to this Agreement including, but not limited to, Worldwide’s invoices shall be available for
inspection and audit by Sponsor as set forth in Section 9.2, or any independent auditors designated by Sponsor, upon ten business
days prior written notice, and for a period of four (4) years following the completion of the Study, unless a longer retention
period is required by Applicable Laws. Sponsor agrees that its independent auditors may be required to execute a reasonable confidentiality
agreement with Worldwide or Worldwide’s Affiliate or subsidiary, as the case may be, which contains mutually agreed-upon
terms. Further, Sponsor’s financial audit of Worldwide or any Worldwide Affiliate or subsidiary hereunder shall be subject
to the confidentiality obligations set forth herein.

 

    Page 10 of 47

     

    

 

		9.2	Audits by Sponsor

 

During
the term of this Agreement, Worldwide will permit representatives of Sponsor who are not competitors of Worldwide to examine, at
reasonable times during normal business hours, subject to at least ten (10) business days prior written notice to Worldwide (except
in the case of “for cause” audits where Sponsor will provide three (3) business days prior written notice to Worldwide),
and at Sponsor’s sole cost and expense: (i) the facilities where the Services are being, will be or have been conducted;
(ii) related Study documentation; and (iii) any other relevant information necessary for Sponsor to confirm that the Services are
being or will be or have been conducted in conformance with applicable standard operating procedures, this Agreement and in compliance
with Applicable Laws and regulations, including related financial information relating to Worldwide service fees, Pass-through
Expenses and grant payments to Investigators. Worldwide will provide copies of any materials reasonably requested by Sponsor during
such inspection.

  

		9.3	Inspection by Regulatory Authorities

 

During the term of this Agreement, Worldwide
will permit regulatory authorities to examine, (i) the facilities where the Services are being conducted; (ii) study documentation;
and (iii) any other relevant information, including information that may be designated by Worldwide as confidential, reasonably
necessary for regulatory authorities to confirm that the Services are being conducted in compliance with Applicable Laws and regulations.
Worldwide will immediately notify Sponsor if any regulatory authority schedules, or without scheduling, begins an inspection that
relates to the Services, and, unless expressly prohibited by such regulatory authority, permit Sponsor to attend such inspection.

 

9.4       Inspections
of Investigator Site(s) by Worldwide

 

In connection with Worldwide’s provision
of Services as specified in this Agreement, Worldwide may conduct monitoring visits and/or inspections of Investigator Sites. Based
on Worldwide’s observations during such Investigator Site visits and inspections, Worldwide may decide: i) that enrollment
should be suspended at the Investigator Site; ii) that an Investigator Site’s non-compliance needs to be reported to Sponsor
and/or regulatory authorities; and/or (iii) Investigator Site’s participation in a Study needs to be terminated. Upon such
a determination, Worldwide will present to Sponsor a basis for its decision. If Sponsor disagrees with the basis for Worldwide’s
decision, Worldwide will assign its contract with the Investigator Site to Sponsor and Sponsor agrees to accept such assignment
and to be responsible for all contractual duties and obligations to the Investigator Site.

  

10.0       INDEMNIFICATION

 

10.1       Indemnification
by Worldwide

 

Worldwide shall indemnify, defend and hold
harmless Sponsor and its Affiliates and their respective officers, directors, employees and agents from any loss, damage, cost
or expense (including reasonable attorney’s fees) (“Losses”) arising from any third party claim, demand,
assessment, action, suit or proceeding (a “Claim”) arising out of (i) any material breach by Worldwide Group
of any material obligations under this Agreement or the Protocol, (ii) any Worldwide Group’s negligence or intentional misconduct;
or (iii) any Worldwide Group’s material failure to comply with any applicable law for FDA regulations, except to the extent
such Losses are caused by Sponsor’s negligence or willful misconduct.

  

    Page 11 of 47

     

    

 

 

 

 

10.2       Indemnification
by Sponsor

 

Sponsor shall indemnify,
defend and hold harmless Worldwide and its Affiliates and their respective officers, directors, employees and agents (the “Worldwide
Group”) from any Losses arising from any Claim arising out of (i) Worldwide’s adherence to written instructions
provided by Sponsor to Worldwide, including adherence to the Protocol and proper performance of the Services in accordance with
this Agreement and the Protocol; (ii) the Study drug’s harmful or otherwise adverse effect, including, without limitation,
a Claim based upon the consumption, sale, distribution or marketing of any substance, including the Study drug, (iii)any breach
by Sponsor of any material obligations under this Agreement, or (iv) the negligence or intentional misconduct of Sponsor, except
to the extent such Losses are caused by Worldwide Group’s negligence or wilful misconduct.

 

In the event Worldwide
incurs reasonable and necessary costs or out-of-pocket expenses as a result of it becoming involved in, or being required to appear
or otherwise participate in, a matter (i) relating to the Study that is the subject of a claim or any proceeding, litigation, arbitration
or some other dispute resolution mechanism, and (ii) where Worldwide’s performance of the Services in a manner other than
in compliance with this Agreement is not at issue in such claim, then Sponsor shall reimburse Worldwide for pre-approved reasonable
and necessary costs or out-of-pocket expenses. The Parties agree to cooperate with each other and to use commercially reasonable
best efforts in good faith to minimize Worldwide’s participation in and the costs or out-of-pocket expenses relating to such
disputes.

 

10.3       Indemnification
Procedures

 

Upon receipt of written
notice of any Claim which may give rise to a right of indemnity from the other Party hereto, the Party seeking indemnification
(the “Indemnified Party”) shall give written notice thereof to the other Party, (the “Indemnifying
Party”). The Indemnified Party shall permit the Indemnifying Party, at its own option and expense, to assume the complete
defense of such Claim, provided that the Indemnified Party will have the right to participate in the defense of any such Claim
at its own cost and expense. As to those Claims with respect to which the Indemnifying Party does not elect to assume control,
the Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense, at the Indemnifying Party’s
own cost and expense.

 

 

11.0       LIMITATION
OF LIABILITY

 

Under no circumstances shall either Party
be liable under this Agreement for any indirect, incidental, special or consequential damages of the other Party resulting from
such Party’s performance or failure to perform under this Agreement. In addition and except for the confidentiality and indemnification
obligations of Worldwide under Sections 5 and 10.1, respectively, in no event shall the collective, aggregate liability of the
Worldwide Group to Sponsor exceed one and one-half times the amount of fees due or actually paid by Sponsor to Worldwide pursuant
to this Agreement.

 

12.0       INSURANCE

 

Sponsor hereby
represents and warrants that it shall maintain adequate clinical trial and product liability insurance coverage, with
insurance companies having an A. M. Best Rating of "A-, VII" or better, consistent with industry standards to cover
all personal injury, death or loss suffered as a result of the Study Drug, participation in the trial or the trial screening
process. Sponsor shall provide Worldwide with a copy of Sponsor’s effective Certificate of Insurance or such other
documented evidence to confirm that it has such coverage. Sponsor shall maintain such insurance for the entire duration of
the Study and shall notify Worldwide of any changes in coverage which impact the coverage requirements set forth above.

 

    Page 12 of 47

     

    

 

Prior to commencement of any work under
this Agreement, Worldwide shall, at its sole expense, maintain the following insurance on its own behalf, with insurance companies
having an A. M. Best Rating of "A-, VII", or better:

 

		(1)	Commercial General Liability (including Premises Operations).
The policy must be on an occurrence form and include the following limits: Each Occurrence: $1,000,000; General Aggregate: $2,000,000.

 

		(2)	Commercial Umbrella Liability. This policy must include
the following limits: Occurrence Limit: $4,000,000; Aggregate Limit (where applicable); $4,000,000 Policy to be excess of the
Commercial General Liability, Commercial Automobile Liability and Employers Liability.

 

		(3)	Product/Professional Liability Coverage (Errors &
Omissions): Each Claim Limit: $ 10,000,000; Aggregate Limit: $10,000,000. Throughout the term of this Agreement, the Errors &
Omissions Liability insurance's retroactive date will be no later than the effective date of this agreement. Upon expiration or
termination of this Agreement, Worldwide will either continue to maintain an active insurance policy, or purchase an extended
reporting period coverage for claims first made and reported to the insurance company within sixty (60) months after the end of
the Agreement.

 

Upon request, Worldwide shall provide Sponsor
with a copy of Worldwide’s Certificates of Insurance or such other documented evidence to confirm that it has all of the
foregoing coverage. Worldwide shall maintain such insurance for the entire duration of the Study and shall notify Sponsor of any
reduction in coverage which impact the coverage requirements set forth above.

 

13.0       REPRESENTATIONS
AND WARRANTIES

 

13.1       Each
Party represents that it is authorized to enter into this Agreement and that the terms of this Agreement are not inconsistent with
or a violation of any contracted or other legal obligation to which it is subject.

 

13.2       Each
Party represents that it has all qualifications, authorizations, licenses or permits which are necessary for performance of its
obligations under this Agreement.

 

13.3       Worldwide
represents and warrants to Sponsor that:

 

(a)       Worldwide
is a duly incorporated and validly existing corporation under the laws of the Delaware;

 

(b)       Worldwide
represents that taken together with its Affiliates it has personnel, equipment, experience and expertise sufficient in quality
and quantity to provide all comprehensive Services requested by Sponsor hereunder and agreed to by Worldwide and its Affiliates
and that any and all such Services will be performed commensurate with the commercially reasonable standards generally applicable
to the conduct and management of clinical drug studies by a clinical research organization throughout the world;

 

(c)       upon
execution and delivery of this Agreement, this Agreement shall constitute a legal, valid and binding agreement of Worldwide
and its Affiliates, as applicable, enforceable in accordance with its terms, except to the extent enforceability may be
affected by applicable bankruptcy, reorganization, insolvency, and moratorium laws and other laws applicable generally to
creditors’ rights and debtors’ remedies from time to time in effect;

 

    Page 13 of 47

     

    

 

(d)       neither
the execution and delivery of this Agreement nor Worldwide’s performance of its obligations hereunder will violate or breach,
or otherwise constitute or give rise to a default under, the terms or provisions of Worldwide’s registration documents or
its By-Laws or any equivalent document or of any material contract, commitment or other obligation to which Worldwide is a party,
or violate or result in a breach of or constitute a default under any judgment, order, decree, rule or regulation of any court
or governmental agency to which Worldwide is subject; and

 

(e)       Worldwide
has developed a business interruption and disaster recovery program and is executing such program to assess and reduce the extent
to which Worldwide’s hardware, software and embedded systems may be susceptible to errors or failures in various crisis (or
force majeure) situations. In the event that any data, reports or materials that are delivered by Worldwide to Sponsor are inaccurate,
and Worldwide does not reasonably dispute such inaccuracy, and such inaccuracy is caused by errors or failures of Worldwide’s
personnel, hardware, software or embedded systems then Worldwide will, to the extent possible, fix, or if necessary, re-perform
the deliverables at its own expense within mutually agreeable time frames. If Sponsor and Worldwide mutually agree that Worldwide
is not capable of timely or satisfactory re-performance and Worldwide has been paid for such Services, then Worldwide will reimburse
Sponsor for the reasonable costs related to a third party’s re-performance of such services or reimburse Sponsor for the
reasonable internal costs allocated for the re-performance of such services; provided, however, such reimbursement shall not exceed
the amount of money Worldwide received for the performance the inaccurate Services.

 

(f)     Worldwide will
employ commercially reasonable efforts to ensure that all data collected and stored by it pursuant to this Agreement will be safeguarded
against loss, damage and destruction arising from any cause including, but not limited to, theft, fire, flood, earthquake, lightning,
and electrical disruption. Such measures and processes will include, but not be limited to, (a) storage of hard-copy documents
and computer storage disks in locked, fireproof containers, and (b) back-up and recovery systems (which are periodically tested)
for computer-based systems. Sponsor has the right, but not the obligation, subject to at least ten (10) business days prior written
notice to Worldwide, during normal business hours and at mutually agreed upon dates and times, to periodically inspect Worldwide’s
premises to determine whether the foregoing measures and processes are in effect and being implemented. Such inspections shall
be subject to the confidentiality obligations set forth herein.

 

14.0        DISCLAIMER

 

Sponsor acknowledges that the results of
the Studies for which the Services are to be provided hereunder are inherently uncertain and that, accordingly, there can be no
assurance, representation or warranty by Worldwide that the product covered by this Agreement can, either during the term of this
Agreement or thereafter, be successfully developed or receive the required approval by the regulatory authorities.

 

Sponsor acknowledges that the development
of the protocol concept and scientific rationale shall be the sole responsibility of Sponsor regardless of Worldwide’s involvement
in Study design or protocol-writing (or lack thereof).

 

    Page 14 of 47

     

    

 

15.0       EMPLOYEES;
NON-SOLICITATION

 

Worldwide’s staff is not, nor shall
they be deemed to be at any time during the term of this Agreement, the employees of Sponsor. In consideration of the fees and
benefits provided in this Agreement, Sponsor agrees that, without Worldwide’s prior written consent, during the term of this
Agreement and for a period of twelve (12) months following its expiration or other termination, neither Sponsor nor any of its
Affiliates shall directly or indirectly solicit for employment or contract, attempt to employ or contract with, or assist any other
entity in employing, contracting with or soliciting for employment or contract any employee who is at that time employed/contracted
by Worldwide and who had been employed/contracted by Worldwide in connection with this Agreement issued hereunder. In the event
that legal action becomes necessary for the enforcement of all or any part of this provision, the prevailing party shall receive
in addition to any other damages or relief awarded, its reasonable attorneys’ fees, together with appropriate costs and interest.
Sponsor acknowledges that in the event of a breach of this Section 15.0, Worldwide shall be entitled to seek injunctive relief
for any such breach.

 

16.0       NOTICES

 

All notices provided for in this Agreement
shall be in English and shall be sent by registered first class mail, postage prepaid, return receipt requested, addressed to the
respective Parties as follows:

 

If to Sponsor:

 

Neurotrope Bioscience, Inc.

205 East 42nd Street,
New York, NY 10019

ATTN: Robert Weinstein

Chief Financial
Officer

Via email:
rweinstein@neurotropebioscience.com

 

If to Worldwide:

 

c/o Worldwide
Clinical Trials, Inc.

3800 Paramount
Parkway, Suite 400, 27560

Morrisville,
NC, United States

ATTN: Legal
Counsel

 

17.0       MISCELLANEOUS

 

17.1        Modification

 

This Agreement may be supplemented, amended
or modified only by mutual agreement of the Parties. No supplement, modification or amendment of this Agreement will be binding
unless it is in writing and signed by both Parties.

 

17.2       Assignment

 

Neither Party shall have the right to
assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other Party,
except that either Party may assign this Agreement to an Affiliate, any purchaser of or successor to that area of its
business to which this Agreement is related, any purchaser of all or substantially all of such Party’s assets or in
excess of 50% of such Party’s voting securities, and any successor corporation resulting from any merger,
consolidation, reorganization, business organization, joint venture or similar transaction of such Party with or into such
corporation. Worldwide assignment, delegation or subcontracting to any third parties shall be in accordance with the terms of
this Agreement. Any permitted assignment by either party will not relieve such Party of its obligations or liability incurred
prior to assignment. Any assignment not in compliance with the terms of this provision shall be void.

 

    Page 15 of 47

     

    

 

17.3       Force
Majeure

 

Neither Sponsor nor Worldwide shall be
liable for delays in performing or any failure to perform any of the terms of this Agreement caused by the effects of fire, strike,
war (declared or undeclared), insurrection, acts of terror, government restriction or prohibition, or other causes reasonably beyond
its control and without its fault, but the Party failing to perform shall use all commercially reasonable efforts to resume performance
of this Agreement as soon as feasible. Any episode of force majeure which continues for 30 days from the date of notification of
its existence shall give the non-affected Party the right to terminate this Agreement upon 30 days additional notice.

 

17.4       Severability

 

If any provision of this Agreement is found
by a court to be void, invalid or unenforceable, the same shall either be reformed to comply with applicable laws and regulations
or stricken if not so conformable, so as not to affect the validity or enforceability of the remaining provisions of this Agreement,
except if the principal intent of this Agreement is frustrated by such reformation or deletion in which case this Agreement shall
terminate.

 

17.5       English
Language

 

Unless the Parties otherwise agree, any
document that is provided in connection with this Agreement must be (a) in English, or (b) accompanied by a certified English translation,
in which case the English translation shall prevail unless the document is a statutory or other official document.

 

17.6       Entire
Agreement

 

The Parties hereto acknowledge that each
has read this Agreement, understands it and agrees to be bound by its terms. The Parties agree that this Agreement is the complete
agreement between the Parties on the subject matter and supersedes all proposals (oral or written), letters of intent, understandings,
representations, conditions, warranties, covenants and other communications between the Parties relating to the same subject matter.

 

17.7       Survival

 

The terms, contained in Section 3, Sections
6.0, 7.6, 8.0, 10.0, 11.0, and 17.0 of this Agreement shall survive the completion of performance, expiration or termination of
this Agreement. Sections 5.0, and 15.0 shall survive for the period expressly set forth in such Section or, if none, the applicable
statute of limitations period applicable to a claim for breach of such provision.

 

17.8       Governing
Law

 

This Agreement shall be interpreted and
enforced in accordance with the laws of the State of Delaware and each Party hereby specifically consents to the personal jurisdiction
thereof.

 

17.9       Waiver

 

No waiver of any term, provision or condition
of this Agreement whether by conduct or otherwise in any one or more instances will be deemed to be construed as a further or continuing
waiver of such term, provision or condition or of any other term, provision or condition of this Agreement.

  

    Page 16 of 47

     

    

 

17.10       Independent
Contractors

 

The Parties’ relationship, as established
by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or
similar business relationship between the Parties. Subject to Section 10.0 and/or as may be expressly agreed otherwise in the case
of legal representation in the EU, neither Party is a legal representative of the other Party, and neither Party can assume or
create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose
whatsoever.

 

17.11       Counterparts

 

This Agreement may be executed in counterparts,
each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. In the
event that any signature is delivered by facsimile transmission, by e-mail delivery of a “.pdf” format data file or
other electronic means, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such signature page were an original thereof.

 

17.12       Arbitration

 

In the event a dispute relating to this
Agreement arises between the Parties, the Parties shall confer in good faith to resolve the dispute through negotiations between
respective senior executives of the Parties. In the event that the Parties are unable to resolve the dispute, the Parties will
attempt to resolve the dispute in good faith through mediation. If the dispute has not been resolved by mediation within sixty
(60) days of the initiation of the procedure, the dispute shall be settled by arbitration administered by the American Arbitration
Association under its Commercial Arbitration Rules in Delaware. Judgment shall be rendered by a mutually agreed upon single arbitrator.
The provisions of this Section may be enforced by any court of competent jurisdiction, and the Party seeking enforcement shall
be entitled to an award of all costs, fees and expenses, including reasonable attorneys’ fees, to be paid by the Party against
whom enforcement is ordered.

 

 

IN WITNESS WHEREOF, the undersigned have
caused this Agreement to be executed by their respective duly authorized representatives effective as of the Effective Date.

 

	NEUROTROPE BIOSCIENCES, INC.	 	WORLDWIDE CLINICAL TRIALS, INC.
	 	 	 
	By:	/s/Robert Weinstein	 	By:	 /s/ Anthony Hinman

 

	Name:	 Robert Weinstein	 	Name:	 Anthony Hinman
	 	 	 
	Title:	 CFO	 	Title:	Legal Counsel
	 	 	 
	Date:	July 23, 2020	 	Date:	July 23, 2020

 

    Page 17 of 47

     

    

 

LIST OF EXHIBITS:

 

	EXHIBIT A:	 	Scope of Services	 
	EXHIBIT B:	 	Timeline	 
	EXHIBIT C:	 	Budget	 
	EXHIBIT D:	 	Payment Schedule	 
	EXHIBIT E:	 	Form of Change Order	 

 

    Page 18 of 47

     

    

 

EXHIBIT A

SCOPE OF SERVICES

 

Assumptions:

 

 

	Study Assumptions and Specifications
	General Study Information	 
	Drug/Compound	Bryostatin
	Indication	Alzheimer's Disease
	Study Phase	 Phase II
	Bid Currency	USD
	 	 
	Study Sites	 
	Number of Countries	1
	Number of Sites	20
	North America	20
	USA	20
	Patients	 
	Number of Screened Patients	220
	Number of Enrolled Patients	100
	Number of Drop Outs	15
	Number of Completed Patients	85
	Site Monitoring and Site Management	 
	Number of CRAs (Headcount Based)	3
	Monitoring Visits	 
	Number of Phone Qualification Visits	10
	Number of Site Qualification Visits	10
	Number of Site Initiation Visits	20
	Number of Remote Monitoring Visits	140
	Number of Interim Monitoring Visits	140
	Pool of Additional Visits	80
	Number of Close-outs Visits	20
	Site Maintenance Months	530
	Remote Data Review	390
	Meetings	 
	Internal Alignment (KO) Meeting	Yes
	Sponsor Alignment (KO) Meeting	Yes
	Project team teleconferences	Yes
	Number of internal teleconferences	82
	Number of sponsor teleconferences	82
	Site Activation	 
	Feasibility/ Site Identification	15
	Essential Documents & Review	20
	Investigator Agreements 	20
	Central Institutional Review Board (IRB) Site Submissions	20
	Medical Affairs	 
	Number of Months for Medical Planning	1

 

 

    Page 19 of 47

     

    

 

	Study Assumptions and Specifications

	Eligibility Review	220 Screened Subjects
	Listings Reviews	100 Enrolled Subjects
	Coded Data Review	100 Enrolled Subjects
	Ongoing Safety Reviews of Labs and ECG alerts	318 Alerts
	Pharmacovigilance	 
	Estimated Number of SAE(s)	11
	Estimated Number of Expedited SUSAR(s)	1
	Safety Database Setup and Maintenance	Argus Database
	Number of Follow-up Reports per Event	2
	Data Management	 
	CRF Pages	 
	Number of Pages/Enrolled Patient	225 Total per Patient

  (30 Unique)
	Number of Pages/Screen Fail Patient	23
	Clinical Data Management System	IBMCD
	Randomization System	IBMCD
	Number of Edit Checks	240
	Number of Dictionary Coding Terms (AEs, MedHistory, Medications)	2,500
	MedDRA Coding	1,000
	WHODRUG Coding 	1,500
	Number of External Vendor Data Loads	26
	Data Cleaning	23565 Pages
	Manual Listings	780
	Reconciliation of SAE(s)	11
	Number and Type of Database Transfers	9 Total Transfers
	Biometrics	 
	Statistical Analysis Plan	Yes
	Randomization Schedule	Yes
	Number and Type of Analyses:	 
	Dry Runs	Yes
	Full Analysis	1
	PK Analysis	Not Included
	Final Analysis Data Displays:	 
	Number of Tables	25 Unique / 50 Repeat
	Number of Listings	25 Unique
	Number of Figures/Graphs	10 Unique / 10 Repeat
	Datasets:	 
	Data sets SDTM	25 Datasets
	Data sets ADaM	15 Datasets
	Ongoing CDISC Transfers	5
	Medical Writing	 
	Informed Consent Form	3
	Clinical Study Report (Shell and body text)	Not Included
	CSR Published	Not Included
	Data Safety Monitoring Board (DSMB)	 
	Number of Meetings	2
	DSMB Data Displays	 

 

    Page 20 of 47

     

    

 

	Study Assumptions and Specifications

	Number of Tables	5 Unique / 18 Repeat
	Number of Listings	11 Unique
	Number of Figures/Graphs	5 Unique / 5 Repeat

 

Responsibilities:

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Feasibility/ Site Identification	X
	Identify Sites	X
	Unblinded Feasibility under Confidentiality Disclosure Agreement	X
	Site Activation Lead Planning Per Country	X
	Liaise with Global Project Lead, Regional Project Manager, Lead Clinical Research Associate and Site Activation Lead to Develop a Site Activation Strategy	X
	Communicate Start-up Timelines	X
	Develop a Risk Log and Priority Action Items	X
	Provide Strategic Input to Site Selection	X
	Develop Site Activation Tracker Template	X
	Trial Master File (TMF) Filing & QC	X
	Regulatory Project Plan	X
	Regulatory Set-up	X
	Set Up Electronic and Hardcopy Files	X
	Familiarize with Protocol, Investigator Brochure and Investigational Medicinal Product Dossier (IMPD)	X
	Set Up Trackers or Databases, Including Country Requirements	X
	Core Documents Master Templates	X
	Develop Master Templates for Core Documents 	X
	Essential Documents & Review (US)	X
	Prepare and Distribute Essential Documents Templates	X
	Customize Essential Document Templates with Site Specific Information	X
	Collect Essential Document from Sites	X
	Provide First Review of Essential Documents for Compliance	X
	Provide Second Review of Essential Documents for Compliance 	X
	Communicate Deficiencies to First Reviewer	X
	Sign Off Essential Documents Package	X
	Answer Questions or Provide Clarification and Training to Project Team on Process or Requirements	X
	Provide Weekly Tracking and Progress Reports	X
	File Essential Documents and Checklist (Electronic Trial Master File/ Trial Master File, Internal Filing)	X
	Essential Documents Review Plan	X
	Essential Documents Checklist	X

 

    Page 21 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility

	Investigator Agreements 	X
	Prepare Template	X
	Negotiate Site Contracts to Execution	X
	Ensure the Completion of Site Indemnification Letters	X
	Administrative Quality Control all Investigator Agreements	X
	Track Status of Investigator Agreements	X
	Coordinate all Required Translations	X
	Investigator Agreements Country Specific Templates	X
	Customize Master Template with Country, Project and Sponsor-specific Requirements 	X
	Arrange Translation into Local Languages	X
	Perform Final Review and Formatting	X
	Contract and Budget Plan (CBP)	X
	Prepare Contract and Budget Plan for Initial Strategy.  Any Substantial Amendments to the Contract and Budget Plan will Require a Contract Amendment	X
	Investigator Grant Build	X
	Build Grant Plan for the Study.  Any Substantial Amendments to the Country and Site Strategy will Require a New Build and Contract Amendment	X
	Submission Strategy & Risk Assessment	X
	Develop Submission Strategy and Perform a Risk Assessment	X
	Central Institutional Review Board (IRB) Site Submissions (US)	X
	Prepare Regulatory Packages for Initial Submission	X
	Complete Application Forms	X
	Quality Control all Packages Prior to Submission	X
	Submit Regulatory Packages to Central Institutional Review Board (IRB)	X
	Track Regulatory Package/ Submission Status	X
	Review & Customize Informed Consent Form	X
	Maintain Informed Consent Form Tracking Log	X
	Central Institutional Review Board (IRB) Submission, Study Level (US)	X
	Preparation of Package, Quality Control, Submission, Response to Queries at Study Level to the Central Institutional Review Board (IRB)	X
	Master Informed Consent Form (ICF) Review	X
	TMF Management Plan & TMF Risk Assessment	X

 

    Page 22 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility

	Draft, Review and Update Trial Master File Management Plan which Includes but is not Limited to:

- Project Timelines and Deliverables, i.e., Target Date of Submission of Trial Master File Documents to the Electronic Trial Master File Inbox by Submitters

- Define Electronic Trial Master File Configuration Requirements

- Delivery Intervals of Wet-ink Documents to Sponsor, if Required, (Quarterly, End of Study, etc.)

- Final Shipment of Trial Master File to Sponsor

- Forwarding applicable Records Management Compliance Standard Operating Procedures to sponsor, if needed.

- Listing of each wet-ink document required to be maintained during the course of the study

- Description of Quality Control/file reviews conducted by the project team

- Description of the Trial Master File close-out process	X
	Approve Trial Master File Management Plan	X
	Worldwide TMF: TMF Set-up: Pre Site Activation Activities	X
	Determine Trial Master File Filing Structure	X
	Review Trial Master File Management Plan for Sponsor-hosted Trial Master Files.  Check for Alignment with Worldwide's Record Management Compliance Standard Operating Procedures	X
	Provide Sponsor with Worldwide's Standard Operating Procedures Describing Trial Master File Document Protection (Scanning for Disaster Recovery), Secure File Area Conditions (Protection Against Fire/ Environmental Factors), and Secure Access to File Area Locations (Controlled and Restricted Access)	X
	Provide Detailed Expectations Regarding Type of Access Requirements of Sponsor and Worldwide's Project Team Including Timeframes for Access and Review	X
	Prepare Annotated Trial Master File Structure	X
	Prepare/ Configure the Trial Master File According to Worldwide's Standard Operating Procedures and Trial Master File Management Plan or Sponsor Plans if Sponsor-hosted Electronic Trial Master File.	X
	Agree Trial Master File Compliance Reporting Needs with the Sponsor	X
	Design Periodic Trial Master File Quality Control Process	X
	Facilitate Electronic Trial Master File System Training of all Users; Provide Project-specific Training Tools to Project Management	X
	Worldwide TMF: TMF Final Reconciliation & Transfer	X
	Complete Final Quality Control and Reconciliation of the Trial Master File	X
	Generate Trial Master File Gap Analysis for Review with Sponsor	X
	Complete a Final Review of the Trial Master File Data Due for Transfer	X
	Transfer Trial Master File Data to Sponsor 	X
	Obtain Signed Transfer of Ownership Form from Sponsor	X

 

    Page 23 of 47

     

    

 

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility

	Internal Alignment (KO) Meeting	X
	Prepare for Internal Alignment Meeting 	X
	Attend and Participate in Meeting	X
	Sponsor Alignment (KO) Meeting	X
	Prepare for Sponsor Alignment Meeting 	X
	Attend and Participate in Meeting	X
	Sponsor Teleconferences	X
	Prepare for Teleconference - Gather Metrics, Issues and Any Action Item Updates	X
	Attend and Participate in Meeting	X
	Internal Teleconferences	X
	Prepare for Teleconference - Gather Metrics, Issues and Any Action Item Updates	X
	Attend and Participate in Meeting	X
	Lead Clinical Research Associate Support	X
	Communicate with Sponsor, Project Team and Vendors	X
	Attend and Participate in the Internal Project Clinical Research Associate (CRA) Training	X
	Provide Project Oversight	X
	Create and Disseminate Project Metrics	X
	Create Study Monitoring Manuals, Plans and Tools 	X
	Review Vendor Portals (Not in Preparation for Site Visit or Meetings)	X
	Provide Ongoing Review of and Updates to Study tools, Trackers, Reports and Metrics	X
	Provide Ongoing Trial Master File Review 	X
	Organizes, Tracks and Ensures the Clinical Study Report is Delivered to All Sites, Institutional Review Boards, and Competent Authorities (In Countries Where Applicable).  Ensures Acknowledgment of Receipts are Available/ Filed.	X
	Site Management	X
	Communicate with Sites During Start-up, Conduct and Closure and Resolve Site Issues Throughout the Study	X
	Support Sites During Start-up, Sites Set-up (Includes Back-up Sites), Conduct and Closure	X
	Update Clinical Trial Management System as Needed	X
	Write Telephone Contact Reports	X
	Communicate with the Project Team Regarding Site Issues	X
	General Site Contact and Communication	X
	Provide Remote Monitoring 	X
	Follow Up with Sites on Protocol Violations/ Deviations and Queries/ Data Management Issues	X
	Provide Assistance with Investigational Medicinal Product (IMP) Site Issues (i.e. Shipment, Acknowledgement, Interactive Response Technologies Site Entry and Review review)	X
	Send/ Deliver Safety Information to Sites (if not performed by the Pharmacovigilance Team)	X

 

    Page 24 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility

	Communicate with Sites Regarding any Serious Adverse Events (SAE) Issues	X
	Provide Electronic Trial Master File Updates on an Ongoing Basis and Quality Control of Site Documents Collected in-between Site Visits	X
	Internal Clinical Research Associate Calls & Project Communication	X
	Clinical Research Associate Training (not at Investigator Meeting)	X
	Remote Pre-site Selection Visits	X
	Prepare for Visit	X
	Perform Visit (Remote)	X
	Write Visit Report	X
	Complete Visit Follow-up	X
	Review and Approve Visit Report	X
	On-site Pre-site Selection Visits	X
	Prepare for Visit	X
	Travel to and from Location	X
	Perform Visit	X
	Write Visit Report	X
	Complete Visit Follow-up	X
	Review and Approve Visit Report	X
	On-site Site Initiation Visits	X
	Prepare for Visit	X
	Travel to and from Location	X
	Perform Visit	X
	Write Visit Report	X
	Complete Visit follow-up	X
	Review and Approve Visit Report	X
	Remote Monitoring Visits Conduct 	X
	Prepare for Visit	X
	Perform Visit (Remote)	X
	Write Visit Report	X
	Complete Visit Follow-up	X
	Review and Approve Visit Report	X
	On-Site Monitoring Visits Conduct	X
	Prepare for Visit	X
	Travel to and from Location	X
	Perform Visit	X
	Write Visit Report	X
	Complete Visit Follow-up	X
	Review and Approve Visit Report	X
	Additional Time On-site	X
	On-site Close-out Visits	X
	Prepare for Visit	X
	Travel to and from Location	X
	Perform Visit	X
	Write Visit Report	X

 

    Page 25 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Complete Visit Follow-up	X
	Review and Approve Visit Report	X
	Reconcile Final Trial Master File	X
	Remote Electronic Data Capture (EDC) Review Conduct	X
	Set-up Grant Payments	X
	Enter New Payees into the Finance System	X
	Acquire and Save all W-9's (US Sites Only)	X
	Process Grant Payments 	X
	Initiate and Print Purchase Orders	X
	Process Check or Wire	X
	Enter Voucher and Payment Transactions into the Finance System	X
	Provide Status Updates	X
	Track and Record all Payments	X
	Process Site Cost Payments 	X
	Set-up Vendor Payments	X
	Enter New Payees into the Finance System 	X
	Acquire and Save all W-9's (US Sites Only)	X
	Process Vendor Payments	X
	Process Check or Wire upon Project Management Approval	X
	Enter Voucher and Payment Transactions into the Finance System	X
	Risk Based Quality Management	X
	Protocol Risk Assessment	X
	Database Set-up & Configuration	X
	Define Argus Database Specifications	X
	Build Database	X
	Test Database	X
	Validate Database	X
	Safety Management Plan Development	X
	Write Safety Management Plan to Define Roles and Responsibilities of the Sponsor and Worldwide and Describe the Procedures for the Management, Processing, and Reporting of Serious Adverse Events (SAE) and Pregnancies	X
	Arrange for Review and Incorporation of Comments	X
	Obtain Approval from All Relevant Parties	X
	Safety Training (Sites, Clinical Research Associates, Project Team)	X
	Develop Training Materials	X
	Train All Relevant Worldwide/ Sponsor/ Site Staff of Pharmacovigilance Requirements and Obligations	X
	Provide Follow-up Training as Required	X
	Serious Adverse Events (SAE) Processing, Investigation, Narrative, Approval & Query Generation 	X
	Assess Each Serious Adverse Event (SAE) for Seriousness, Listedness and Causality	X
	Review Coding, Querying and Narratives and Analyze Similar Events	X

 

    Page 26 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility

	Provide Approval and Follow-up on each Serious Adverse Event (SAE)	X
	Analysis of Similar Events (AOSE) (US SUSARs only)	X
	Safety Management Maintenance	X
	Maintain and Update the Safety Management Plan as Necessary to Define Roles and Responsibilities of the Sponsor and Worldwide and Describe the Procedures for the Management, Processing, and Reporting of Serious Adverse Events (SAE) and Pregnancies	X
	 Review and Incorporate Updated Comments	X
	Approve Updates 	X
	Preparation of Line Listings (LL)	X
	Prepare and Write the Line Listings and Annual Safety Reports	X
	Review and Incorporate Comments	X
	Approve Updates 	X
	Suspected Unexpected Serious Adverse Reaction (SUSAR)/ Annual Safety Reports (ASR)/ Line Listings (LL) submission to Investigators	X
	Arrange for the Timely Submission of Pharmacovigilance Documents to Relevant Investigators to Ensure Regulatory Compliance	X
	DSUR Preparation (Writing and Compiling)	X
	Pharmacovigilance Closeout	X
	Arrange for the Preparation of Pharmacovigilance Data Stored in Argus to be Transferred to the Sponsor	X
	Deliver Data Safety Monitoring Board (DSMB) Database & Tables, Figures & Listings (TFLs)	X
	DSMB Statistical Analysis Plan (SAP)	X
	DSMB Unique Tables	X
	Create Unique Study Tables (One Draft)	X
	Validate Unique Study Tables	X
	Finalize Unique Study Tables After Sponsor Review	X
	Validate Final Unique Study Tables	X
	DSMB Repeat Tables	X
	Create Repeat Study Tables (One Draft Post Database Lock)	X
	Validate Repeat Study Tables	X
	Finalize Repeat Study Tables After Sponsor Review	X
	Validate Final Repeat Study Tables	X
	DSMB Unique Listings	X
	Create Unique Study Listings (One Draft Post Database Lock)	X
	Validate Unique Study Tables	X
	Finalize Unique Study Listings After Sponsor Review	X
	Validate Final Unique Study Listings	X
	DSMB Unique Figures	X
	Create Unique Study Figures (One Draft Post Database Lock)	X
	Validate Unique Study Figures	X
	Finalize Unique Study Figures After Sponsor Review	X
	Validate Final Unique Study Figures	X

 

    Page 27 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's

 Responsibility
	DSMB Repeat Figures	X
	Create Repeat Study Figures (One Draft Post Database Lock)	X
	Validate Repeat Study Figures	X
	Finalize Repeat Study Figures After Sponsor Review	X
	Validate Final Repeat Study Figures	X
	Medical Planning	X
	Review the Protocol and Investigator Brochure to Gain an Understanding of the Trial	X
	Prepare Medical Monitoring Plan	X
	Provide Additional Study Document Review and Comment 	X
	Prepare and Conduct Clinical Research Associates (CRA) Training	X
	Communicate with Vendors to Determine Specifications Documents (Normal Ranges, Alerts Set-up, etc.)	X
	Medical Management	X
	Communicate with Sites/ Clinical Research Associates/ Project Team/ Sponsor on Protocol-medical Issues	X
	Document and Log Discussions	X
	Review Protocol Deviation Log	X
	Eligibility Review	X
	Review Selected Screening Datasets for Prospective Assessment of Eligibility	X
	Develop Subject Eligibility Form	X
	Discuss Process Design	X
	Listings Reviews	X
	Provide Adverse Events (AE), Serious Adverse Events (SAE), Medical History, Concomitant Medications, Vital Signs, Demographics Listings Review. Assumes One Cycle.	X
	Coded Data Review	X
	Provide Medical Review of Non-direct Hits for Medical Coding of Adverse Events, Concomitant Medications and Medical History	X
	Ongoing Safety Reviews of Labs and ECG Alerts	X
	Review Predefined Lab and Electrocardiogram Alerts	X
	Follow Up with Sites as Needed	X
	Maintain Medical Monitor Log	X
	Data Management Plan	X
	Prepare Data Management File and Filing of Trial Master File Documents	X
	Draft Data Management Plan for Sponsor Approval	X
	Training	X
	Electronic Case Report Form (eCRF) Development	X
	Create Database/ Electronic Data Capture (EDC)/ Electronic Case Report Form (eCRF)Specifications	X
	Electronic Case Report Form (eCRF) Completion Guidelines	X
	Draft Electronic Case Report Form Completion Guidelines and Electronic Data Capture Training Manuals for Sponsor Approval	X
	Edit Check Specifications	X

 

    Page 28 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Specify Electronic, Manual and Statistical Analysis Software (SAS) Data Validation Checks	X
	Manual Listings Creation	X
	User Acceptance Testing	X
	Define Electronic Data Capture (EDC) Roles and Responsibilities (Study Attributes)	X
	Build and Validate Data Management Database	X
	Conduct User Acceptance Testing of Database	X
	Program and Validate Electronic, Manual and SAS Data Validation Checks	X
	Set-up of Standard Reports	X
	Provide Specification, Creation and Running of Data Management Reports	X
	User Manual Development	X
	Electronic Data Capture (EDC) Support	X
	Manage Access to Study-specific Electronic Data Capture (EDC)	X
	Train Users on EDC	X
	Provide Site Support (Access and eCRF Questions)	X
	Serious Adverse Event (SAE) Reconciliation	X
	Program and Validate SAE Reconciliation Program	X
	Serious Adverse Event (SAE) Reconciliation Maintenance	X
	Run SAE Reconciliation Program	X
	Resolve Issues that Arise from SAE Reconciliation	X
	Data Cleaning	X
	Provide Data Cleaning and Listing Review	X
	Reconcile Database and Clean Local Lab Normal Ranges	X
	Manual Listing Review	X
	Vendor Reconciliation Set-up	X
	Draft Data Transfer Agreement	X
	Programming and Validation of Reconciliation Program	X
	User Acceptance Testing of Reconciliation Process	X
	Vendor Reconciliation Maintenance	X
	Upon Receipt of Data for Reconciliation, Run Reconciliation Programs	X
	Resolve Issues that Arise from Reconciliation with Vendors	X
	Vendor Integration Set-up	X
	Draft Data Transfer Agreement	X
	Program and Validate Integration Program	X
	Conduct User Acceptance Testing of Integration Process	X
	Upon Receipt of Data for Integration, Run Integration Programs	X
	Resolve Issues that Arise from Integration with Vendors	X
	Vendor Integration Maintenance	X
	Upon Receipt of Data for Reconciliation, Run Reconciliation Programs	X
	Resolve Issues that Arise from Integrations	X
	MedDRA Coding (via Coding Tool within EDC)	X
	Provide Medical Coding and Raise Appropriate Queries	X
	Manage Dictionary	X

 

    Page 29 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's

 Responsibility
	WHODRUG Coding (via Coding Tool within EDC)	X
	Provide Medical Coding and Raise Appropriate Queries	X
	Manage Dictionary	X
	Coding Dictionary Updates	X
	Data Transfer Set-up	X
	Create Data Transfer Programs and Transfer of Data During the Course of the Study	X
	Data Transfers	X
	Database Lock	X
	Conduct Database Quality Assessments	X
	Provide Data Report	X
	Create Database Lock Authorization Form	X
	Lock Database	X
	Provide Database Lock Report	X
	Conduct Final Data Transfer of Raw Data	X
	Distribute PDFs of Electronic Case Report Forms (eCRF) to the Sites and Sponsor for Archiving	X
	Archive CDs	X
	Randomization/ Kit list/ Interactive Response Technologies Review	X
	Create Randomization Specification	X
	Create and Validate One Dummy Randomization	X
	Create and Validate One Final Randomization	X
	Data Management Specifications	X
	Review One Draft of the Data Management Deliverables (eCRFs, Edit Checks, Database Set-up) for Appropriate and Necessary Data Collection with a Focus Towards Study Objectives and Endpoints	X
	Statistical Analysis Plan & Mock Shells	X
	Create One Draft Statistical Analysis Plan (SAP), Formatted, to be Inserted Directly into the Methods Section of an ICH-E3 Compliant Clinical Study Report	X
	Create One Draft of Table and Listing Shells for Each Unique Table and Listing	X
	Quality Control Draft Statistical Analysis Plan (SAP) and Table and Listing shells	X
	Create Final Statistical Analysis Plan (SAP) and Final Table and Listing Shells	X
	Study Data Tabulation Model (SDTM) Datasets	X
	Provide Study Data Tabulation Model (SDTM) Datasets from Raw Data Files Provided by the Data Management Team in Accordance with the Clinical Data Interchange Standards Consortium (CDISC) Implementation Guide and Worldwide's Standards (If Sponsor-specific Standards are Required Information Should be Provided at the Beginning of the Project)	X
	Create Dataset Specifications Document	X
	Create One Draft Version of SDTM Datasets	X

 

    Page 30 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Validate Draft Version of SDTM Datasets via Independent Quality Control and Open CDISC	X
	Create One Final Version of SDTM Datasets	X
	Validate Final Version of SDTM Datasets via Independent Quality Control and Open CDISC	X
	Analysis Datasets	X
	Provide Analysis Data Model (ADaM) Datasets (Or Derived Datasets) Based on SDTM Data,  Implementation Guide and Worldwide's Standards (If Sponsor-specific Standards are Required Information Should be Provided at Project Outset)	X
	Create Dataset Specifications Document	X
	Create One Draft Version of ADaM Datasets	X
	Validate Draft Version of ADaM Datasets via Independent Quality Control	X
	Create One Final Version of ADaM Datasets	X
	Validate Final Version of ADaM Datasets via Independent Quality Control	X
	Define.xml and Data Reviewers Guide for SDTM, Annotated CRF	X
	Create One Draft and One Final “Define.xml” Document for SDTM Datasets	X
	Create One Draft and One Final “Define.xml” Document for ADaM Datasets	X
	Create One Draft and One Final Annotated CRF, Annotated with the Variables in the SDTM Datasets	X
	Create One Draft and One Final Study Data Reviewers Guide, Adding Further Detail to the SDTM Datasets	X
	Create One Draft and One Final Analysis Data Reviewers Guide, Adding Further Detail to the ADaM Datasets	X
	Deliver Final Database & Table, Figures & Listings	X
	Final Unique Study Tables	X
	Create Unique Study Tables (One Draft Post Database Lock)	X
	Validate Unique Study Tables	X
	Finalize Unique Study Tables After Sponsor Review	X
	Validate Final Unique Study Tables	X
	Final Repeat Study Tables	X
	Create Repeat Study Tables (One Draft Post Database Lock)	X
	Validate Repeat Study Tables	X
	Finalize Repeat Study Tables After Sponsor Review	X
	Validate Final Repeat Study Tables	X
	Final Unique Study Listings	X
	Create Unique Study Listings (One Draft Post Database Lock)	X
	Validate Unique Study Listings	X
	Finalize Unique Study Listings After Sponsor Review	X
	Validate Final Unique Study Listings	X
	Final Unique Study Figures	X
	Create Unique Study Figures (One Draft Post Database Lock)	X
	Validate Unique Study Figures	X

 

    Page 31 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Finalize Unique Study Figures After Sponsor Review	X
	Validate Final Unique Study Figures	X
	Final Repeat Study Figures	X
	Create Repeat Study Figures (One Draft Post Database Lock)	X
	Validate Repeat Study Figures	X
	Finalize Repeat Study Figures After Sponsor Review	X
	Validate Final Repeat Study Figures	X
	Statistical Input to Clinical Study Report (CSR)	X
	Delivery Dry Run Database & Table, Figures & Listings	X
	Model Inform Consent Form(s) (ICF(s))	X
	Obtain Final Protocol	X
	Establish Template to be Utilized	X
	Generate First Draft for Sponsor Review	X
	Generate Second Draft for Sponsor Approval	X
	Deliver Final Model Informed Consent Form	X
	Scale Identification and Acquisition	X
	Contact Copyright Holder to Identify/ Acquire Scales (Including Translated Versions as Applicable)	X
	Approve Correct Scales Acquired	X
	Coordinate with Contracts to Obtain Scales	X
	Creation of Source Documents	X
	Apply Header/ Footer to Scales	X
	Coordinate with Regulatory for Ethics Committees/ Institutional Review Board Submission	X
	Approve Source Documents	X
	Make Scales Available for Use by Sites	X
	Approve Scales	X
	Rater Training Plan	X
	Develop Rater Training Plan (Methodology, Experience Requirements)	X
	Approve Rater Training Plan	X
	File Rater Training Plan into Trial Master File	X
	Develop Rater Training Database/ Tracker	X
	Create Rater Experience Qualification (Survey)	X
	Rater Experience Verification	X
	Work with Project Team to Develop Process for Obtaining Potential Site Raters to Complete Rater Experience Qualification (Survey)	X
	Distribute Rater Experience Qualification (Survey)	X
	Collect Rater Experience Qualification (Survey) from Sites	X
	Review Rater Experience against Rater Training Plan	X
	Recommend Next Steps for Proposed Raters Who do Not Meet Sponsor-agreed-Qualifications	X
	Approve Raters for Study Who do Not Meet Sponsor-agreed Qualifications (Overrides)	X
	File Rater Experience Qualification (Survey) Forms into the Trial Master File	X
	Rater Training and Certification	X

 

    Page 32 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Track/ Manage Raters at Each Site	X
	Process Investigator Meeting Raters for Training/ Certification	X
	Process New Raters for Training/ Certification throughout the study	X
	Follow Up with Raters to Complete Training/ Certification	X
	Issue Training/ Certification Certificates	X
	File Training/ Certification Certificates into the Trial Master File	X
	Applied Skill Assessment (ASA) not at Investigator Meeting	X
	Instructions for Site Raters on How to Submit Applied Skills Assessment (ASA) to Worldwide	X
	Clinical Review and Feedback for Applied Skills Assessment (ASA)	X
	Complete Applied Skills Assessment Form (For Each Rater's ASA)	X
	File Applied Skills Assessment Form into the Trial Master File	X
	Coordinate Next Steps with Sponsor when Rater Fails the Applied Skills Assessment	X
	Didactic Presentation	X
	Develop Didactics for the Study	X
	Approve Didactics	X
	Web Portal	X
	Define Requirements for Study Web Portal	X
	Provide Training Materials to be Uploaded to the Web Portal	X
	Develop/ Configure Study Web Portal	X
	User Acceptance Test Study Web Portal	X
	Data Surveillance Plan	X
	Develop Data Surveillance Plan (Methodology)	X
	Approve Data Surveillance Plan	X
	Develop Source Document Review Database/ Tracker	X
	Develop EDC Monitoring Database/ Tracker	X
	Set-up of Clinical Assessment Technologies EDC Data Monitoring System	X
	Provide Data Management with Flags to be Programmed into EDC/ SAS	X
	Develop and Test EDC/ SAS Flags	X
	Define Requirements for EDC Monitoring Reports	X
	Develop and Test EDC Monitoring Reports	X
	Clinical Assessment Technologies Data Management Reports	X
	Electronic Data Capture (EDC) Flag Clinical Review	X
	Provide Clinical Review of Flagged Subject Visits	X
	Collection & Review of Source Documents	X
	Document Interactive Response Technology Notifications in Source Document Database/ Tracker	X
	Collect Source Documents from Sites for Clinical Review	X
	Follow Up with Sites for Missing (Not Submitted) Source Documents	X
	Review Clinical Source Documents	X
	Clinical Assessment Start-up & Planning	X

 

    Page 33 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Clinical Assessment Maintenance & Reporting	X
	Clinical Assessment Technologies Virtual Training Session 	X
	Confirm Attendees and Communication Details	X
	Create and Distribute Invitation to Attend Training Sessions	X
	Conduct Virtual Training Sessions	X
	Close Out Virtual Training Sessions (Document Attendees, Distribute Training Certificates)	X
	Pre go-live Project Management, Requirements Gathering & Design (SaaS)	X
	Lead Interactive Response Technology-focused Gathering Meetings	X
	Write User Requirements Specifications According to Protocol Design	X
	Write Interactive Response Technology Project Plan	X
	Configuration/Coding (SaaS)	X
	Configure Interactive Response Technology System for Study According to Specifications	X
	Write Custom Code if Required	X
	Validation (SaaS)	X
	Develop Test Plan	X
	Perform Testing of System Against Specifications	X
	Review testing materials	X
	Review and Sign Test Plan	X
	Review and Sign Test Summary Report (Including a Review of any Defects)	X
	Systems Integrations (SaaS)	X
	Manage the Set-up of Any Integrations Between Interactive Response Technology and Other Systems 	X
	Coordinate Data Transfers	X
	Configure and Test Integration	X
	Sponsor User Acceptance Testing (SaaS)	X
	Set Up Data for User Acceptance Testing	X
	Facilitate the Performance of User Acceptance Testing for the Sponsor	X
	Interactive Response Technologies Inventory Implementation and Review	X
	Interactive Response Technology Project Management (SaaS)	X
	Oversight and Accountability for the Project	X
	Act as Point of Escalation for Any Interactive Response Technology-related Issues for the Study	X
	Production Support (SaaS)	X
	Daily Support of Interactive Response Technology	X
	Production Randomization Monitoring and Audit	X
	Monitoring Patient and Material Randomization to Ensure Correct Execution in Production	X
	Decommissioning (SaaS)	X

 

    Page 34 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Coordinate Decommissioning of the System and Data Archiving at End of Study	X
	Clinical Trial Management System (CTMS) Set-up	X
	Develop User Requirement Specifications	X
	Monitoring Visit Report (MVR) Review and Configuration	X
	CTMS OnPoint and SharePoint Build/ Configuration	X
	CTMS OnPoint and SharePoint User Acceptance Testing	X
	Create Study-specific Guides	X
	Create System Alerts	X
	Develop Sponsor Training Slides	X
	Create Study Specific Access Form	X
	Submit Documents to the eTMF as required	X
	Conduct Study Team Q&A Session	X
	Conduct Sponsor Training	X
	Clinical Trial Management System Helpdesk/ Maintenance	X
	Administer Required Training	X
	Grant CTMS User and Study Access	X
	Respond to CTMS service desk requests	X
	Support MVR Issues and Changes	X
	Edge Payments Customization	X
	Edge Payments Maintenance, Support, Changes	X
	Grant System Access	X
	Respond to Helpdesk Queries	X
	Add Sites	X
	Edge Payments Maintenance, Support, Changes	X
	Rater Web Portal Set-up	X
	Rater Web Portal Maintenance, Support, Changes	X
	Create Study Specific Integration documents for Interactive Response Technologies to EDC	X
	Create Study Specific Integration documents for EDC to OnPoint CTMS	X
	Integration Set-up	X
	Project Management - Start-up	X
	Identify Sites/ Principal Investigators 	X
	Create or Review Project Plans	X
	Execute Project Plans	X
	Prepare for and Plan Site Training	X
	Provide and Receive Project-specific Training (Develop Training, Presenting, Receive Training, Includes Protocol Review Time)	X
	Set Up Internal/ External Systems	X
	Review Sponsor Standard Operating Procedures	X
	Review Scope of Work and Finalize Study Specifications	X
	Develop Project Timelines	X
	Prepare for and Attend Internal and External Meetings and Calls Including Agenda/ Minute Preparation	X
	Prepare and Distribute Study Newsletters and Other Site Communications	X

 

    Page 35 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's 

Responsibility
	Maintain and Quality Control Trial Master File (Including Response to Internal or Sponsor Audits) and Deliver to Sponsor	X
	Manage Study Vendors (Includes Identification, Selection, Contract Negotiation and Management)	X
	Complete all Project-related Internal System Data Entry such as Time Entry, Monthly Operational Reviews, Resource Planning, Financial Tracking or Other Internal Systems	X
	Prepare Site/ Study Documents (Site Reference Material, Study Binders, Recruitment Tools)	X
	Manage Site Supplies	X
	Manage Site Grant and Principal Investigator Reimbursement Payments (Includes Initiating Grant Fund Replenishment Invoicing Requests and Approval of Payments)	X
	Complete Revenue Reporting and Projections	X
	Manage Changes to Contracts	X
	Procure Invoice Approval (Includes Follow-up Internally or with Sponsor	X
	Manage Vendor Payments	X
	Complete Financial Reconciliation	X
	Monitor, Evaluate and Adjust Key Performance Indicators	X
	Generate Status Reports	X
	Track Project-related Data to Facilitate and Inform Status Reporting and Study Management	X
	Project Management - Conduct	X
	Oversee Patient Recruitment	X
	Prepare for and Plan Investigator Meeting (For Those Occurring after Start-up)	X
	Participate in and Present at Investigator Meeting (For Those Occurring after Start-up)	X
	Oversee the Management, Monitoring, Adjustment and Ongoing Revision of Project Plans (Updates to Study Plans, Review of Risks and Identification of New Mitigation Strategies)	X
	Provide and Receive Project-specific Training (Develop Training, Presenting, Receive Training, Includes Protocol Review Time)	X
	Oversee Changes to Internal/ External Systems	X
	Revise Project Timelines	X
	Prepare for and Attend Internal and External Meetings and Calls including Agenda/ Minute Preparation	X
	Prepare and Distribute Study Newsletters and Other Site Communications	X
	Maintain and Quality Control Trial Master File (Including Response to Internal or Sponsor Audits) and Deliver to Sponsor	X
	Manage Study Vendors (Includes Identification, Selection, Contract Negotiation and Management)	X
	Complete all Project-related Internal System Data Entry such as Time Entry, Monthly Operational Reviews, Resource Planning, Financial Tracking or Other Internal Systems	X

 

    Page 36 of 47

     

    

 

	Worldwide Clinical Trials Responsibility Matrix
	Task	Worldwide's

 Responsibility
	Prepare Site/ Study Documents (Site Reference Material, Study Binders, Recruitment Tools)	X
	Manage Site Supplies	X
	Manage Site Grant and Principal Investigator Reimbursement Payments (Includes Initiating Grant Fund Replenishment Invoicing Requests and Approval of Payments)	X
	Complete Revenue Reporting and Projections	X
	Manage Changes to Contracts	X
	Procure Invoice Approval (Includes Follow-up Internally or with Sponsor	X
	Manage Vendor Payments	X
	Complete Financial Reconciliation	X
	Monitor, Evaluate and Adjust Key Performance Indicators	X
	Generate Status Reports	X
	Track Project-related Data to Facilitate and Inform Status Reporting and Study Management	X
	Project Management - Close-out	X
	Oversee the final management, monitoring, adjustment and ongoing revision of project plans	X
	Provide and receive Project Specific Training (develop training, presenting, receive training)	X
	Revise Project Timelines	X
	Prepare for and attend Internal and External Meetings and Calls including Agenda/Minute Preparation	X
	Prepare and Distribute Site Communications	X
	Maintain and Quality Control Trial Master File (Including Response to Internal or Sponsor Audits) and Deliver to Sponsor	X
	Manage Study Vendors 	X
	Complete all Project-related Internal System Data Entry 	X
	Prepare Site/ Study Documents 	X
	Manage Site Supplies	X
	Manage Site Grant and Principal Investigator Reimbursement Payments 	X
	Complete Revenue Reporting and Projections	X
	Manage Changes to Contracts	X
	Procure Invoice Approval (Includes Follow-up Internally or with Sponsor	X
	Manage Vendor Payments	X
	Complete Financial Reconciliation	X
	Monitor, Evaluate and Adjust Key Performance Indicators	X
	Generate Status Reports	X
	Track Project-related Data to Facilitate and Inform Status Reporting and Study Management	X

 

    Page 37 of 47

     

    

 

 

EXHIBIT B

TIMELINE

 

	Study Timeline	Estimated Start Date	Estimated End Date	Duration (Months)
	Commencement of Work (Start Date)	20-Apr-2020	 	 
	Protocol Finalized	1-Jun-2020	 	 
	Study Start-up	20-Apr-2020	27-Sep-2020	5.3
	Patient Enrollment Period	28-Sep-2020	14-Sep-2021	11.6
	Patient Active Treatment	15-Sep-2021	3-Oct-2022	12.6
	Patient Follow-up Phase	4-Oct-2022	4-Oct-2022	0.0
	Last eCRF Submitted to Data Management	5-Oct-2022	2-Nov-2022	1.0
	Database Lock	3-Nov-2022	15-Nov-2022	0.4
	Final Tables, Listings, Figures/Graphs	16-Nov-2022	5-Jan-2023	1.7
	Final Clinical Study Report	6-Jan-2023	13-Mar-2023	2.2
	Total Study Duration (Months)	 	 	34.6

 

    Page 38 of 47

     

    

 

EXHIBIT C

BUDGET

 

	 	 	 	 
	 	 	 	Service Agreement Budget
	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD
	Site Activation	 	 	 	 
	o	Feasibility/ Site Identification	Site	15.00	784.00	11,760.00
	o	Site Activation Lead Planning Per Country	Country	1.00	2,268.00	2,268.00
	o	Site Activation Lead Oversight - Start Up Phase	Site Months	106.00	226.80	24,040.80
	o	Site Activation Lead Oversight - Conduct Phase	Site Months	510.00	98.60	50,286.24
	o	Trial Master File (TMF) Filing & QC	Site/Quarter	196.00	311.24	61,002.86
	o	Regulatory Project Plan	Plan	1.00	2,270.00	2,270.00
	o	Regulatory Set-up	Study	1.00	3,450.00	3,450.00
	o	Regulatory Tracking & Follow-up	Country/Month	31.00	151.55	4,698.05
	o	Core Documents Master Templates	Study	1.00	3,995.00	3,995.00
	o	Essential Documents & Review (US)	Site	20.00	2,513.50	50,270.00
	o	Essential Documents Review Plan	Plan	1.00	2,334.00	2,334.00
	o	Essential Documents Checklist	Country	1.00	131.50	131.50
	o	Investigator Agreements 	CTA	20.00	1,644.75	32,895.00
	o	Investigator Agreements Country Specific Templates	Country Template	1.00	1,352.00	1,352.00
	o	Contract and Budget Plan (CBP)	Plan	1.00	985.00	985.00
	o	Investigator Grant Build	Build	1.00	2,750.00	2,750.00
	o	Submission Strategy & Risk Assessment	Country	1.00	1,393.00	1,393.00
	o	Central Institutional Review Board (IRB) Site Submissions (US)	Site	20.00	667.00	13,340.00
	o	Central Institutional Review Board (IRB) Submission, Study Level (US)	Study	1.00	944.00	944.00
	o	Central IRB Site Submissions (US)- Yearly Maintenance	Site/Year	58.00	314.00	18,212.00
	o	Central IRB Submissions (Study Level)- Yearly Maintenance	Study/Year	3.00	236.00	708.00
	o	Central IRB Site Submissions (US)- End of Trial Notifications	Site	20.00	157.00	3,140.00
	o	Central IRB Submissions (Study Level)- End of Trial Notifications	Study	1.00	59.00	59.00
	o	Master Informed Consent Form (ICF) Review	ICF	3.00	1,816.00	5,448.00
	o	Translation Coordination	Language	1.00	1,416.00	1,416.00
	 	Sub-Total Study Site Activation	 	 	 	299,148.45
	Trial Master File	 	 	 	 
	o	TMF Management Plan & TMF Risk Assessment	Plan	1.00	700.00	700.00
	o	Worldwide TMF: TMF Set-up: Pre Site Activation Activities	Sites	20.00	525.00	10,500.00
	o	Worldwide TMF: TMF Maintenance & QC	Site Months	623.00	56.49	35,192.66
	o	Worldwide TMF: TMF Final Reconciliation & Transfer	Sites	20.00	379.57	7,591.32
	 	Sub-Total Trial Master File	 	 	 	53,983.98

 

    Page 39 of 47

     

    

 

	 	 	 	Service Agreement Budget
	 	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD
	Project Meetings	 	 	 	 

	o	Internal Alignment (KO) Meeting	Meeting	1.00	14,628.00	14,628.00
	o	Sponsor Alignment (KO) Meeting	Meeting	1.00	15,681.00	15,681.00
	o	Webex Trainings	Meeting	2.00	1,385.00	2,770.00
	o	Sponsor Teleconferences	Teleconferences	82.00	1,098.17	90,050.02
	o	Internal Teleconferences	Teleconferences	82.00	1,098.17	90,050.02
	 	Sub-Total Project Meetings	 	 	 	213,179.04
	Clinical Monitoring	 	 	 	 
	o	Lead Clinical Research Associate Support	Month	33.00	12,101.75	399,357.69
	o	Site Management	Site Months	530.00	595.19	315,451.58
	o	Internal Clinical Research Associate Calls & Project Communication	Month	28.00	1,013.20	28,369.62
	o	Clinical Research Associate Training (not at Investigator Meeting)	Attendee	4.00	1,478.00	5,912.00
	o	Remote Pre-site Selection Visits	Visit	10.00	1,013.00	10,130.00
	o	On-site Pre-site Selection Visits	Visit	10.00	3,283.50	32,835.00
	o	On-site Site Initiation Visits	Visit	20.00	3,675.50	73,510.00
	o	Remote Monitoring Visits Conduct 	Visit	140.00	950.92	133,129.10
	o	On-Site Monitoring Visits Conduct	Visit	140.00	4,257.43	596,040.30
	o	Additional Time On-site	Visit	80.00	820.61	65,648.69
	o	On-site Close-out Visits	Visit	20.00	4,216.46	84,329.15
	o	Remote Electronic Data Capture (EDC) Review Conduct	Site Months	390.00	181.60	70,824.60
	 	Sub Total Clinical Monitoring	 	 	 	1,815,537.73
	Grant & Vendor Payments	 	 	 	 
	o	Set-up Grant Payments	Contract	20.00	110.00	2,200.00
	o	Process Grant Payments 	Payment	480.00	66.39	31,866.78
	o	Process Site Cost Payments 	Site	20.00	55.00	1,100.00
	o	Set-up Vendor Payments	Vendor	3.00	102.00	306.00
	o	Process Vendor Payments	Month	57.00	54.34	3,097.20
	 	Sub-Total Grant & Vendor Payments	 	 	 	38,569.98
	Risk Based Quality Management	 	 	 	 
	o	Protocol Risk Assessment	Risk Assessment	1.00	14,224.58	14,224.58
	 	Sub Total Quality Assurance Audits	 	 	 	14,224.58
	Drug Safety 	 	 	 	 
	o	Database Set-up & Configuration	Database	1.00	3,640.00	3,640.00
	o	Safety Management Plan Development	Plan	1.00	3,957.00	3,957.00
	o	Safety Training (Sites, Clinical Research Associates, Project Team)	Training	1.00	1,039.50	1,039.50
	o	Serious Adverse Events (SAE) Processing, Investigation, Narrative, Approval & Query Generation 	SAE	11.00	1,693.39	18,627.29
	o	Analysis of Similar Events (AOSE) (US SUSARs only)	SUSAR Report	1.00	496.12	496.12
	o	Safety Management Maintenance	Month	32.00	1,530.63	48,980.30
	o	Preparation of Line Listings (LL)	Report	1.00	650.02	650.02

 

    Page 40 of 47

     

    

 

	 	 	 	Service Agreement Budget
	 	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD

	o	Suspected Unexpected Serious Adverse Reaction (SUSAR)/ Annual Safety Reports (ASR)/ Line Listings (LL) submission to Investigators	Country * Submissions	3.00	160.63	481.88
	o	DSUR Preparation (Writing and Compiling)	DSUR	3.00	12,577.16	37,731.48
	o	Pharmacovigilance Closeout	Transfer	1.00	3,336.17	3,336.17
	 	Sub-Total Drug Safety 	 	 	 	118,939.76
	Data Safety Monitoring Board (DSMB)	 	 	 	 
	o	Deliver Data Safety Monitoring Board (DSMB) Database & Tables, Figures & Listings (TFLs)	 Delivery 	2.00	22,667.24	45,334.48
	 	DSMB Statistical Analysis Plan (SAP)	 Plan 	1.00	11,770.88	11,698.28
	 	DSMB Unique Tables	 Unique Table 	5.00	1,534.49	7,672.43
	 	DSMB Repeat Tables	 Repeat Table 	18.00	604.87	10,887.73
	 	DSMB Unique Listings	 Unique Listing 	11.00	938.77	10,326.51
	 	DSMB Unique Figures	 Unique Figure 	5.00	2,816.32	14,081.61
	 	DSMB Repeat Figures	 Repeat Figure 	5.00	930.77	4,653.86
	 	Sub-Total Data Safety Monitoring Board 	 	 	 	104,654.90
	Medical Monitoring	 	 	 	 
	o	Medical Planning	Month	1.00	23,050.00	23,050.00
	o	Medical Management	Screened Subject	220.00	215.88	47,492.90
	o	Eligibility Review	Screened Subject	220.00	479.73	105,539.78
	o	Listings Reviews	Enrolled Subject	100.00	119.93	11,993.16
	o	Coded Data Review	Enrolled Subject	100.00	19.19	1,919.11
	o	Ongoing Safety Reviews of Labs and ECG Alerts	Alert	318.00	167.91	53,396.71
	o	Maintain Medical Monitor Log	Month	24.00	1,144.69	27,472.66
	 	Sub-Total Medical Monitoring	 	 	 	270,864.32
	Data Management	 	 	 	 
	o	Data Management Plan	Plan	1.00	3,474.00	3,474.00
	o	Training	Study	1.00	3,264.00	3,264.00
	o	Electronic Case Report Form (eCRF) Development	Unique Pages	30.00	601.65	18,049.50
	o	Electronic Case Report Form (eCRF) Completion Guidelines	Database	1.00	3,088.00	3,088.00
	o	Edit Check Specifications	Edit Check	240.00	80.31	19,274.40
	o	Manual Listings Creation	Listing	30.00	959.00	28,770.00
	o	User Acceptance Testing	Database	1.00	7,720.00	7,720.00
	o	Set-up of Standard Reports	Study	1.00	7,672.00	7,672.00
	o	User Manual Development	Study	1.00	1,544.00	1,544.00
	o	Electronic Data Capture (EDC) Support	Users	60.00	128.33	7,699.86
	o	Serious Adverse Event (SAE) Reconciliation	SAE	11.00	193.00	2,123.00
	o	Serious Adverse Event (SAE) Reconciliation Maintenance	Months	26.00	99.64	2,590.65
	o	Data Cleaning	Total Pages	23,565.00	1.24	29,204.50
	o	Manual Listing Review	Listings	780.00	100.69	78,538.32

 

    Page 41 of 47

     

    

 

	 	 	 	Service Agreement Budget
	 	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD

	o	Vendor Reconciliation Set-up	Vendor	2.00	3,072.00	6,144.00
	o	Vendor Reconciliation Maintenance	Upload	51.00	586.90	29,931.82
	o	Vendor Integration Set-up	Integration	1.00	3,446.00	3,446.00
	o	Vendor Integration Maintenance	Upload	26.00	586.90	15,259.37
	o	MedDRA Coding (via Coding Tool within EDC)	Terms	1,000.00	4.03	4,032.41
	o	WHODRUG Coding (via Coding Tool within EDC)	Meds	1,500.00	8.05	12,082.22
	o	Coding Dictionary Updates	Year	2.00	1,610.97	3,221.93
	o	Data Transfer Set-up	Database	1.00	384.00	384.00
	o	Data Transfers	Transfer	9.00	400.66	3,605.90
	o	Database Lock	Database Lock	1.00	7,801.85	7,801.85
	o	Archive CDs	Site	20.00	86.13	1,722.51
	o	Data Management Coordination	Month	31.00	1,610.97	49,940.15
	 	Sub-Total Data Management	 	 	 	350,584.39
	Biostatistics	 	 	 	 
	o	Randomization/ Kit list/ Interactive Response Technologies Review	 List 	2.00	6,024.00	12,048.00
	o	Data Management Specifications	 Protocol 	1.00	6,574.55	6,574.55
	o	Statistical Analysis Plan & Mock Shells	 Plan 	1.00	17,893.58	17,893.58
	o	Study Data Tabulation Model (SDTM) Datasets	 Dataset 	25.00	2,688.39	67,209.84
	o	Analysis Datasets	 Dataset 	15.00	3,353.40	50,300.93
	o	Define.xml and Data Reviewers Guide for SDTM, Annotated CRF	 Specification 	5.00	5,084.93	25,424.65
	o	Deliver Final Database & Table, Figures & Listings	 Delivery 	1.00	7,643.93	7,643.93
	 	Final Unique Study Tables	 Unique Table 	25.00	1,544.01	38,600.23
	 	Final Repeat Study Tables	 Repeat Table 	50.00	608.63	30,431.36
	 	Final Unique Study Listings	 Unique Listing 	25.00	944.60	23,614.97
	 	Final Unique Study Figures	 Unique Figure 	10.00	2,833.80	28,337.97
	 	Final Repeat Study Figures	 Repeat Figure 	10.00	936.55	9,365.46
	o	Statistical Input to Clinical Study Report (CSR)	 CSR 	1.00	6,425.06	6,425.06
	o	Delivery Dry Run Database & Table, Figures & Listings	 Delivery 	1.00	15,315.15	15,315.15
	 	Sub-Total Biostatistics	 	 	 	339,185.68
	Medical Writing	 	 	 	 
	o	Model Inform Consent Form(s) (ICF(s))	ICF(s)	3.00	8,204.00	24,612.00
	 	Sub-Total Medical Writing	 	 	 	24,612.00
	Clinical Assessment Technologies	 	 	 	 
	o	Scale Identification and Acquisition	 Scale 	6.00	1,029.00	6,174.00
	o	Creation of Source Documents	 Language* Scale 	12.00	429.63	5,155.50
	o	Rater Training Plan	 Plan 	1.00	2,805.00	2,805.00
	o	Rater Experience Verification	 Rater 	43.00	96.75	4,160.25
	o	Rater Training and Certification	 Rater 	34.00	182.50	6,205.00

 

    Page 42 of 47

     

    

 

	 	 	 	Service Agreement Budget
	 	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD

	o	Applied Skill Assessment (ASA) not at Investigator Meeting	 ASA*Rater 	34.00	275.88	9,379.75
	o	Didactic Presentation	 Presentation  	1.00	1,438.38	1,438.38
	o	Web Portal	 Portal 	1.00	6,043.10	6,043.10
	o	Data Surveillance Plan	 Plan 	1.00	13,985.50	13,985.50
	o	Set-up of Clinical Assessment Technologies EDC Data Monitoring System	 System 	1.00	9,837.50	9,837.50
	o	Clinical Assessment Technologies Data Management Reports	 Month 	24.00	398.57	9,565.71
	o	Electronic Data Capture (EDC) Flag Clinical Review	 Visit 	384.00	215.41	82,715.84
	o	Collection & Review of Source Documents	 Visit * Scale 	244.00	151.25	36,905.00
	o	Clinical Assessment Start-up & Planning	 Month 	5.00	1,798.25	8,991.25
	o	Clinical Assessment Maintenance & Reporting	 Month 	24.00	938.13	22,515.01
	o	Clinical Assessment Technologies Virtual Training Session 	 WebEx 	2.00	6,306.00	12,612.00
	 	Sub-Total Clinical Assessment Technologies	 	 	 	238,488.79
	Interactive Response Technology	 	 	 	 
	o	Pre go-live Project Management, Requirements Gathering & Design (SaaS)	Build	1.00	15,484.00	15,484.00
	o	Configuration/Coding (SaaS)	Build	1.00	5,856.00	5,856.00
	o	Validation (SaaS)	Build	1.00	8,928.00	8,928.00
	o	Review testing materials	Build	1.00	996.00	996.00
	o	Systems Integrations (SaaS)	Build	1.00	15,680.50	15,680.50
	o	Sponsor User Acceptance Testing (SaaS)	Build	1.00	10,368.00	10,368.00
	o	Interactive Response Technologies Inventory Implementation and Review	Build	1.00	1,732.00	1,732.00
	o	Interactive Response Technology Project Management (SaaS)	Month	26.00	3,443.50	89,530.88
	o	Production Support (SaaS)	Month	26.00	4,732.71	123,050.37
	o	Production Randomization Monitoring and Audit	System	1.00	3,662.73	3,662.73
	o	Decommissioning (SaaS)	System	1.00	2,197.64	2,197.64
	 	Sub-Total Interactive Response Technology	 	 	 	277,486.12
	Technology	 	 	 	 
	o	Clinical Trial Management System (CTMS) Set-up	System	1.00	10,927.00	10,927.00
	o	Clinical Trial Management System Helpdesk/ Maintenance	Month	35.00	892.08	31,222.89
	o	Edge Payments Set-up: Grant Payments	System	1.00	2,848.00	2,848.00
	o	Edge Payments Customization	System	1.00	4,895.00	4,895.00
	o	Edge Payments Maintenance, Support, Changes	Month	24.00	278.58	6,685.89
	o	Rater Web Portal Set-up	System	1.00	19,353.00	19,353.00
	o	Rater Web Portal Maintenance, Support, Changes	Month	29.00	536.29	15,552.44

 

    Page 43 of 47

     

    

 

	 	 	 	Service Agreement Budget
	 	Services	Unit	# Units	Unit Cost 

USD	Total Cost USD

	o	Integration Set-up	System	1.00	36,093.00	36,093.00
	o	Integration Maintenance, Support, Changes	Month	29.00	406.92	11,800.68
	 	Sub-Total Technology	 	 	 	139,377.90
	Project Management 	 	 	 	 
	o	Project Management - Start-up	Month	5.00	22,531.57	112,657.83
	o	Project Management - Conduct	Month	24.00	19,571.52	469,716.40
	o	Project Management - Close-out	Month	5.00	16,116.23	80,581.15
	 	Sub-Total Project Management	 	 	 	662,955.38
	 	 	 	 	 	 
	 	Total Estimated Service Fees	 	 	 	4,961,793.00
	 	 	 	 	 	 
	 	Discount	 	 	 	-372,134.48
	 	 	 	 	 	 
	 	Total Estimated Service Fees including Discount	 	 	 	4,589,658.53
	 	 	 	 	 	 
	System & General Expenses	 	 	 	 
	o	IBMCD Electronic Data Capture (EDC) Maintenance & Hosting	Month	29.00	6,000.00	174,000.00
	o	Argus Safety Database Set-up & Configuration	System	1.00	15,000.00	15,000.00
	o	Argus Safety Database Hosting	Month	25.51	2,116.82	54,000.00
	o	Clinical Trial Management System User Access	System	1.00	3,000.00	3,000.00
	o	IBMCD IRT System Fees	System	1.00	14,500.00	14,500.00
	o	Electronic Trial Master File (eTMF) Monthly Hosting Fees	Site months	733.00	35.00	25,655.00
	o	Regulatory System Fees	Site	31.00	387.10	12,000.00
	Total System & General Expenses	 	 	 	298,155.00
	 	 	 	 	 	 
	Estimated Pass-through Costs	 	 	 	 
	 	 	 	 	 	 
	Study Start-up Pass-through Costs	 	 	 	 
	o	Print and Ship Investigator Site File to Sites	Site	20.00	300.00	6,000.00
	o	Institutional Review Board (IRB) Site Regulatory Documents (includes preparation, collection, annual renewals if needed)	 	 	 	 
	 	North America - Central IRB	Site	20.00	1,500.00	30,000.00
	 	Sub-Total Start-up Pass-through Costs	 	 	 	36,000.00
	Clinical Monitoring Pass-through Costs	 	 	 	 
	o	Pre-site Selection Visits	Visit	10.00	700.00	7,000.00
	o	Site Initiation Visits	Visit	20.00	700.00	14,000.00
	o	Interim Monitoring Visits	Visit	140.00	700.00	98,000.00
	o	Additional Time on Site	Visit	80.00	700.00	56,000.00
	o	Close-Out Visits	Visit	20.00	700.00	14,000.00
	o	Site Management	Site Months	530.00	10.00	5,300.00
	 	Sub Total Study Conduct Pass-through Costs	 	 	 	194,300.00

 

    Page 44 of 47

     

    

 

	 	 	 	 	 
	Services	Unit	 # Units	Unit Cost 

USD	Total Cost USD
	Clinical Assessment Technologies Pass-through Costs	 	 	 	 
	o	Scale Licenses	License	6.00	7,567.50	45,405.00
	o	Scale Translations	Scales* Languages	1.00	2,500.00	2,500.00
	o	Rater Experience Surveys/Trial Interactive	Raters*Surveys	10.00	10.00	100.00
	 	Sub-Total Clinical Assessment Technologies Pass-through Costs	 	 	 	48,005.00
	Archiving Pass-through Costs	 	 	 	 
	o	Shipment of Completed Case Report Forms (CRF) Back to Sites (archive copy, disc for EDC)	Shipment	20.00	50.00	1,000.00
	o	Shipment of Completed electronic Case Report Forms (eCRF)Back to Sponsor (disc )	Shipment	1.00	50.00	50.00
	 	Sub-Total Archiving Pass-through Costs	 	 	 	1,050.00
	Trial Master File Pass-through Costs	 	 	 	 
	o	Final Transfer of Study Records to Sponsor (Disk)	Transfer	1.00	150.00	150.00
	 	Sub-Total Project Management Pass-through Costs	 	 	 	150.00
	Project Management Pass-through Costs	 	 	 	 
	o	Project Management Passthrough Costs	Month	35.00	100.00	3,500.00
	 	Sub-Total Project Management Pass-through Costs	 	 	 	3,500.00
	Third Party Vendor Costs	 	 	 	 
	o	Central Lab: ACM	Study	1.00	248,814.00	248,814.00
	o	ECG Provider: ERT	Study	1.00	114,000.00	114,000.00
	o	Avantor Sciences (ballpark)	Study	1.00	40,000.00	40,000.00
	 	Sub-Total Third Party Vendors	 	 	 	402,814.00
	PI Fees	 	 	 	 	 
	o	Investigator Grants- Completed patients	Patient	85.00	37,304.00	3,170,840.00
	o	Investigator Grants- Screen failure patients	Patient	120.00	3,645.50	437,460.00
	o	Investigator Grants- Dropped patients	Patient	15.00	21,548.40	323,226.00
	o	Site Costs	Site	20.00	13,032.00	260,640.00
	 	Sub-Total PI Fees	 	 	 	4,192,166.00
	Total Estimated Pass-Through Costs	 	 	 	4,877,985.00
	 	 	 	 	 	 
	Total Estimated Budget	 	 	 	9,765,798.53
	Note that the unit costs are derived from the total cost after regional & annual rates have been applied and therefore result in a blended rate.	 

 

    Page 45 of 47

     

    

 

EXHIBIT D

PAYMENT SCHEDULE

 

1.      
Service Fees:

 

		1.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, upon signature of this Work
Order, Sponsor will pay Worldwide an advance payment of $488,781.35 due upon ten (10) days of receipt, (advance payment represents
10% of the Service Fee and System and General Expenses total). All subsequent invoices will be submitted to Sponsor by email monthly
based on units completed in the preceding month according to the Budget above, with each subsequent invoice for Service Fees and
System and General Expenses reduced by 10% until the advance payment is exhausted. With the exception of the first payment described
above in the amount of $488,781.35, payment terms shall be as defined in this Agreement. Any outstanding balances will be reconciled
at the end of the Study.

 

		1.2.	The bottom line discount (“Discount”) shall be defined as a one-time discount applied
to the service fees of this study budget, based on the current scope and specifications detailed within this Work Order. Should
these parameters vary from what is presented within, Worldwide reserves the right to adjust any discounts or commercial incentives
based on the revised scope and budget values.

 

		1.3.	Payment shall be issued by check or wire transfer at Sponsor’s option. Wiring instructions are as follows:

 

	 	Account Holder:	 	Worldwide Clinical Trials, Inc.
	 	Bank Name:	 	HSBC Bank USA, NA
	 	Bank Address:	 	445 North Bedford Dr.
	 	 	 	Beverly Hills, CA 90210
	 	ABA Routing No.:	 	021001088
	 	Bank Account No.:	 	167-74758-4
	 	Swift Code:	 	MRMDUS33
	 	Taxpayer ID#: 	 	26-0902850

 

2.      
Pass-through Expenses:

 

		2.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, Worldwide shall invoice Sponsor
an advance payment of $137,163.80 due upon ten (10) days of receipt (advance payment represents 20% of the anticipated Pass-through
Expenses). Worldwide will submit subsequent monthly invoices by email for incurred Pass-through Expenses based on actuals, with
each subsequent invoice for Pass-through Expenses reduced by 20% until the advance payment is exhausted. With the exception of
the first payment described above in the amount of $137,163.80 payment terms shall be as defined in this Agreement. Any outstanding
balances will be reconciled at the end of the Study.

 

3.      
Investigator/Institution Fees:

 

		3.1.	Notwithstanding the payment terms in Section 3.4 of the Agreement, Worldwide shall invoice Sponsor
an advance payment of $314,412.45 due upon ten (10) days of receipt (advance payment represents 7.5% of the anticipated Investigator/Institution
grants). Periodically, Worldwide will invoice Sponsor by email to replenish this advance back-up to an amount equivalent to 7.5%
of the anticipated Investigator/Institution grants or such other amount of funds needed to bring the balance to the sufficient
amount to ensure that payments are made to sites in a timely manner. The invoice will be accompanied by a report which itemizes
the Investigator/Institution grants that have been paid in the period, and will reconcile the use of funds received from Sponsor.
If an increase in the amount of anticipated Investigator/Institution grants is necessary, Worldwide will provide appropriate support
justifying such increase. Any outstanding balances will be reconciled and provided no earlier than 30 days after at the end of
the Study. For avoidance of doubt, Worldwide will make all grant payments only from funds received from Sponsor specifically for
this purpose. Worldwide shall not be liable for any payments delays due to the delay in receipt of funds from Sponsor.

 

    Page 46 of 47

     

    

 

EXHIBIT E

FORM OF CHANGE ORDER

 

	Client:
    	Worldwide
    Project Manager:
	Protocol
    Number:	Worldwide
    ID:
	Change
    Order #: 	Date:
    

 

Worldwide Clinical Trials, Inc.
(“Worldwide”) and Neurotrope Bioscience, Inc. (“Sponsor”) entered into an agreement dated [effective
date] (“Agreement”) [as amended by Change Order # 1 effective [effective date]] [and further amended by Change
Order # 2 effective [effective date]] in which Worldwide was to provide certain Services to Sponsor in connection with Study
[insert Protocol number] (“Study”). Worldwide and Sponsor wish to amend the Agreement as follows:

 

1. Revisions to the Scope of Services.
The Scope of Services has been revised as described below, and Worldwide will provide the following additional services [will
not provide the following services initially contracted]:

 

	Description
    of Service	Cost
	 	 
	 	 

 

2. Revisions to the Study Budget. As a
result of the changes to the Services and Scope of Services, this Change Order # [Insert] [increases] [decreases] the Service
fees as shown above. A revised total budget value is below.

 

	 	Services
    Fees	Estimated
    Pass Through Costs	Total
	Original
    Agreement Value:	 	 	 
	Change
    Order #1 Value:	 	 	 
	[Add
    additional Change Orders as necessary]	 	 	 
	Revised
    Contract Value:	 	 	 

 

3. Revisions to the Payment Schedule.
A revised and restated payment schedule, as amended by Change Order # [Insert#] is detailed below.

 

Payment
Schedule, as amended by Change Order # [Insert]

 

Except to the extent specifically
modified by this Change Order # [Insert], the provisions of the Agreement remain unmodified and the Agreement as amended by this
Change Order # [Insert] is confirmed as being in full force and effect. All defined terms within the Agreement shall have the
same meaning when used herein.

 

Authorized representatives of
the Parties have executed this Change Order # [insert] effective as of the Effective Date written above.

 

	Worldwide
    Clinical Trials, Inc.	 	Neurotrope
    Bioscience, Inc.
	 	 	 
	By:	Sample	 	By:	Sample

 

	Name:	 	 	Name:	 
	 	 	 
	Title:	 	 	Title:	 
	 	 	 
	Date:	 	 	Date:	 

 

    Page 47 of 47Lease

 

EXHIBIT 10.3

LEASE

1.

Parties. This lease (this "Lease") is made and entered into this 1st day of September, 2020, by and between Wewards, Inc., a Nevada corporation ("Tenant") and Future Property Limited ("Landlord").

2.

Premises. Landlord leases to Tenant and Tenant leases from Landlord the building (the "Building"), and improvements, located at 2960 West Sahara Avenue, in Las Vegas, Nevada 89102, and further described as Clark County Assessor's Parcel Numbers 162-05-816-011 (the "Land") together with the use and benefit of all of Landlord's rights, privileges and easements. The Land including the Building is herein referred to as the "Premises".

3.

Term. The term of this Lease shall commence on September 1st, 2020 (the "Commencement Date") and shall expire effective as of 11:59 p.m. (PST) on the date that is two (2) years and six (6) months thereafter (the "Term"). 

4.

Base Rent; Monthly Additional Rent.

(a)

During the Term, Tenant shall pay to Landlord, all monthly base rent (the "Base Rent") as provided in Section 4(b) and Monthly Additional Rent as provided in Section 4(c) (collectively "Rent") on the first day of each and every calendar month commencing on the Commencement Date. All Rent shall be paid in lawful currency of the United States of America, to Landlord at Landlord's address set forth in Section 15, or at such other address as the Landlord may specify in writing from time to time during the Term of this Lease.

(b)

Base Rent in the amount of $15,000 per month shall be payable monthly in advance commencing on the Commencement Date, and continuing on or before the first day of each calendar month during the Term without offset or deduction, except as may be otherwise expressly provided in this Lease. If the Commencement Date is not the first day of a calendar month, Rent for the period from the Commencement Date to the first of the next calendar month shall be pro-rated on a per diem basis and paid on the Commencement Date.

5.

Use, Compliance with Law, Condition of Premises.

(a)

Use.

Tenant may use the Premises for any legal purpose, including, without limitation, for general office and administrative activities of Tenant and its affiliates.

(b)

Compliance with Law.

(i)

Landlord’s Obligations. Except for Tenant's obligations pursuant to Section 5(b)(ii), Landlord, throughout the Term of this Lease, shall comply with all covenants or restrictions of record (if any), or any applicable building codes, laws, ordinances, orders, rules and regulations whether state, federal, municipal or promulgated by other agencies or bodies having jurisdiction over the Premises (the "Legal Requirements") concerning the Premises.

1

 

(ii)

Tenant’s Obligations. Tenant, at Tenant's sole cost and expense, shall comply with the Legal Requirements pertaining to the Premises if such compliance is required solely as a result of Tenant's unique business use conducted within the Premises.

(c)

Condition of Premises. Landlord shall deliver the Premises to Tenant clean and free of debris on the Commencement Date and represents and warrants to Tenant:

(i)

the Premises is free from defects, is in fully functional condition for the purpose for which it was used prior to the date hereof, with no material maintenance, repair or replacement having been deferred or neglected, is suitable for its current use and free from other material defects.

(ii)

all public utilities necessary for the use and operation of the existing facilities on the Premises are available for use or access at the Premises and there is no legal or physical impairment to free ingress or egress from any of the Premises.

If a non-compliance with said warranty exists as of the Commencement Date, Landlord shall promptly after receipt of written notice from Tenant setting forth with specificity the nature and extent of such non-compliance, rectify same at Tenant's expense.

6.

Repair and Maintenance Responsibilities.

(a)

Landlord, at Landlord's sole cost and expense, shall keep the Building's roof, shell, structure, exterior walls, interior columns, and foundation in good condition and repair. If Landlord does not promptly commence such repairs, maintenance and replacement required of Landlord within thirty (30) days following written notice thereof from Tenant and continue to diligently pursue completion thereof, Tenant shall have the right, but not the obligation, to complete such repairs, maintenance, or replacement. Landlord agrees that all of its work shall not (i) damage the appearance or reduce the floor area of the Premises, (ii) affect Tenant's layout (including access to the Premises), or (iii) materially interfere with Tenant's use and enjoyment of the Premises. Landlord shall perform all such work in such a way as to minimize disruption to Tenant's business.

(b)

Except as otherwise set forth in Section 6(a), Tenant shall, at its expense, keep the entire Premises in good repair and maintenance (including replacements) at all times, including repair, replace and maintain the interior of the Building including walls, doors, floors, ceilings, light bulbs, florescent tubes, cabinets, and all mechanical and electrical portions of the Building including, but not limited to, the heating, ventilation and air conditioning (HVAC), electrical, elevators, sprinkler system and standard plumbing systems, in the condition they existed in on the Commencement Date, loss by fire or ordinary wear and tear excepted. If Tenant does not promptly commence such repairs, maintenance and replacement required of Tenant within thirty (30) days following written notice thereof from Landlord and continue to diligently pursue completion thereof, Landlord shall have the right, but not the obligation, to complete such repairs, maintenance or replacement, in which event the costs and expenses related thereto shall be billed directly to and paid by Tenant to Landlord within thirty (30) days after receipt of such billing. In the event there is any warranty in effect in connection with repairs, maintenance, or replacements made by Tenant and if Landlord is unwilling to honor and/or pursue the warranty claim, as appropriate, then Tenant shall have the right to pursue the warranty claim in connection with the repair, maintenance, or replacements made by Tenant.

2

 

7.

Assignment and/or Subletting. Tenant shall not voluntarily assign or encumber its interest in this Lease or in the Premises, or sublease all or any part of the Premises, or allow any other person or entity (except Tenant's authorized representatives) to occupy or use all or any part of the Premises, without first obtaining Landlord's written consent, which consent shall not be unreasonably withheld or delayed. Any assignment, encumbrance or sublease without Landlord's written consent, which consent shall not be unreasonably withheld or delayed, shall be voidable and, at Landlord's election, shall constitute a default. No consent to any assignment, encumbrance or sublease shall constitute a further waiver of the provisions of this Section. Notwithstanding the foregoing, Tenant shall have the right to assign this Lease and/or sublet any part or all of the Premises, without the Landlord's consent, to any of Tenant's subsidiary(s), joint venture partner(s), partnership(s), or other affiliated entity(s), and/or to a successor(s) in interest to any part and/or all of Tenant's business including, without limitation, a sale of assets or stock (a "Permitted Transfer"). A Permitted Transfer shall include a merger or consolidation with another entity and/or an assignment or subletting to another entity which is controlling Tenant, controlled by Tenant or is under common control of Tenant and other entity. Regardless of Landlord's consent, no assignment or sublease shall release Tenant of Tenant's obligations hereunder.

8.

Termination of Insurance, Tenant’s Insurance, Landlord’s Insurance, Mutual Release/Waiver of Subrogation, and Indemnity.

(a)

Termination of Insurance. Any insurance required by this Section shall contain a provision that the insurance cannot be terminated without thirty (30) days prior written notice to the other party. All insurance required under this Section shall be maintained with insurance companies qualified to do business in the state in which the Premises are located and otherwise reasonably acceptable to the other party. As evidence of the existence of any insurance required under the Lease, each party shall provide the other with a certificate of insurance or other reasonably satisfactory evidence of such insurance coverage.

(b)

Landlord’s Insurance. Landlord shall maintain policies of insurance covering loss of or damage to the Premises in the full amount of its replacement cost value (the "Building Insurance"). Such policy shall provide protection against all perils included within the classification of fire, extended coverage, vandalism, malicious mischief, special extended perils (all risk), sprinkler leakage and any other perils which Landlord deems reasonably necessary. Any such policy may contain a standard loss payable clause in favor of the holder of any mortgage on the Premises. Landlord shall only utilize insurance companies that are rated no less than "A-, X" by A.M. Best or equivalent rating agency. Landlord shall not obtain insurance for Tenant's fixtures or equipment or Building improvements installed by Tenant on the Premises or other property. Landlord shall pay the premiums for the Building Insurance and rental income insurance policies maintained by Landlord. Landlord shall advise Tenant of the annual premium for such insurance and Tenant shall pay as Monthly Additional Rent a sum equal to one-twelfth (1/12) of the annual premium therefore each month to be paid with the monthly rent installments due hereunder. Promptly upon any change in the amount of such premiums, Landlord shall notify Tenant of such change and the amount to be paid by Tenant shall be adjusted accordingly.

3

 

(c)

Mutual Release/Waiver of Subrogation. Landlord and Tenant each hereby release the other from any and all liability or responsibility for any loss, injury or damage to the Premises, or its contents caused by fire or any other casualty during the Term of this Lease, even if such fire or casualty may have been caused by the negligence (but not the willful misconduct) of the other party or one for whom such party may be responsible. Inasmuch as the above mutual waivers will preclude the assignment of any aforesaid claim by way of subrogation (or otherwise) to an insurance company (or any other person), each party hereto hereby agrees if required by said policies to give to each insurance company which has issued to it policies of fire and extended coverage insurance, written notice of the terms of said mutual waivers, and to have said insurance policies properly endorsed, if necessary, to prevent the invalidation of said insurance coverage by reason of said waivers.

(d)

Indemnity.

(i)

Tenant shall indemnify and hold Landlord and its officers, directors, partners and employees entirely harmless from and against any and all liabilities, claims and/or losses of any kind arising, directly or indirectly, entirely or in part, out of any injury to any person occurring within the Premises regardless of the cause, except to the extent caused by the negligence or intentional misconduct of Landlord, Landlord's agents, employees, invitees or contractors. In the event that any action or proceeding is brought against Landlord by reason of any such claim, Tenant, upon receipt of written notice from Landlord, shall defend the same, at Tenant's expense, by counsel reasonably satisfactory to Landlord. Notwithstanding anything in this Lease to the contrary, the foregoing covenants under this Section 8(e)(i) shall be deemed continuing covenants for the benefit of Landlord and shall survive the expiration of the Lease but only to the extent that the causes giving rise to Tenant's obligations under this Section 8(e)(i) occur before the expiration of this Lease.

(ii)

Landlord shall indemnify and hold Tenant and its officers, directors, partners and employees entirely harmless from and against any and all liabilities, claims and/or losses of any kind arising, directly or indirectly, entirely or in part, out of any injury to any person occurring any place within the Premises to the extent caused by the negligence or intentional misconduct of Landlord, Landlord's agents, employees, invitees or contractors. In the event that any action or proceeding is brought against Tenant by reason of any such claim, Landlord, upon receipt of written notice from Tenant, shall defend the same, at Landlord's expense, by counsel reasonably satisfactory to Tenant. Notwithstanding anything in this Lease to the contrary, the foregoing covenants under this Section 8(e)(ii) shall be deemed continuing covenants for the benefit of Tenant and shall survive the expiration of the Lease but only to the extent that the causes giving rise to Landlord's obligations under this Section 8(e)(ii) occur before the expiration of this Lease.

4

 

9.

Default/Remedies.

(a)

Tenant’s Default. The occurrence of any one or more of the following shall constitute a default hereunder by Tenant:

(i)

failure to pay Rent when due if the failure continues for five (5) days after written notice has been received by Tenant;

(ii)

failure to perform any other provision of this Lease if such failure to perform is not cured within fifteen (15) days after written notice has been received by Tenant, provided that, if the default cannot reasonably be cured within fifteen (15) days, Tenant shall not be in default of this Lease if Tenant commences to cure the default within the fifteen (15) day period and diligently and in good faith continues to cure the default;

(iii)

any proceeding is begun by or against Tenant to subject the assets of Tenant to any bankruptcy or insolvency law or for an appointment of a receiver of Tenant or of any of Tenant's assets and is not dismissed within ninety (90) days; or

(iv)

Tenant makes a general assignment of Tenant's assets for the benefit of creditors.

Notices given under this Section shall specify the alleged default and the applicable Lease provision(s), and shall demand that Tenant perform the provisions of this Lease or pay the Base Rent or Monthly Additional Rent that is in arrears, as the case may be, within the applicable period of time.

(b)

Landlord’s Remedies. In the event of any such default by Tenant, Landlord may at any time after expiration of the applicable cure period:

(i)

terminate Tenant's right to possession of the Premises by any lawful means, in which case this Lease and the Term hereof shall terminate and Tenant shall surrender possession of the Premises to Landlord within a reasonably practical period of time thereafter. In such event, notwithstanding any such termination, Landlord shall be entitled to recover from Tenant all reasonable damages incurred by Landlord by reason of Tenant's default including, without limitation, Base Rent as contemplated by Section 9(b)(iv), the cost of recovering possession of the Premises; expenses of reletting, including reasonable and necessary renovation and alteration of the Premises, reasonable attorney's fees, and any real estate commission actually paid; and any other sum of money, late charges and damages owed by Tenant to Landlord;

(ii)

maintain Tenant's right to possession in which case this Lease shall continue in effect. In such event Landlord shall be entitled to enforce all of Landlord's rights and remedies under this Lease, including the right to recover the Base Rent as it becomes due hereunder; or

5

 

(iii)

pursue any other remedy now or hereafter available to Landlord under the laws or judicial decisions of the state where the Premises are located.

(iv)

Notwithstanding the foregoing, in no event shall Landlord be entitled to damages in excess of the outstanding balance of Base Rent due and payable during the remainder of the then existing Term up to a maximum amount of six (6) months of Base Rent for the remainder of the Term.

(v)

In the case of Tenant's default as contemplated herein, Landlord shall have a duty to mitigate its damages hereunder in good faith.

(c)

Tenant’s Remedies. Should there be any breach of this Lease on the part of Landlord, in the event Landlord fails to cure the breach within thirty (30) days after Tenant gives Landlord written notice thereof or, if such breach cannot be reasonably cured within thirty (30) days, in the event Landlord fails to commence within thirty (30) days and thereafter diligently pursue to completion the cure of such breach, then Tenant in addition to its remedies at law or in equity, including, curing the breach and the reasonable cost thereof shall be payable from Landlord to Tenant upon demand, offsetting any amounts owed by Landlord against Rent due hereunder and terminating the Lease by written notice to the Landlord.

10.

Utilities and Services. Tenant shall pay directly to the appropriate supplier, the cost of all natural gas, light, power, sewer, telephone, water, refuse disposal and other utilities and services supplied to the Premises.

11.

Real Property Taxes. Landlord shall pay all real property taxes payable with respect to the Premises during the Term. Landlord shall compute, based upon the most recently available real estate tax billing information available, the annual amount of such real estate taxes and advise Tenant of the amount thereof. Tenant shall pay to Landlord as Monthly Additional Rent during the Term hereof with each monthly installment of rent an amount of money equal to one-twelfth (1/12) of the annual amount of real estate taxes as reasonably calculated by Landlord. When real estate tax bills are actually received, any adjustments between the Landlord's estimated amount and the actual real estate taxes shall be promptly computed, and if additional funds are owing by Tenant, such funds shall be paid by Tenant to Landlord within thirty (30) days of being advised of the amount thereof. If the amounts collected therefore are greater than the amounts required to be paid by Landlord, Landlord shall promptly so advise Tenant and such sum shall be treated as a credit against any sums which may then or hereafter become owing to Landlord hereunder.

12.

Damage or Destruction. Should the Premises be damaged by fire or other casualty, the following shall result:

(a)

Should the Premises be rendered wholly unfit for occupancy and not be (in the reasonable judgment of Landlord and Tenant) susceptible of repair within sixty (60) days after the date of such damage, this Lease, upon written notice from either party to the other, shall terminate as of the date of such damage, and Tenant shall pay Rent hereunder apportioned to the time of such damage and surrender the Premises to Landlord within a reasonably practical period of time thereafter;

6

 

(b)

Should such damage to the Premises, however, be (in the reasonable judgment of Landlord and Tenant) susceptible of repair within sixty (60) days after such occurrence or this Lease is not terminated pursuant to Section 12(a), Landlord, at Landlord's sole cost and expense, shall enter and make repairs, without affecting this Lease, but the Rent hereunder shall be reduced or abated as shall be equitable while such repairs are being made.

Damage to the Building which affects Tenant's access to the Premises or Tenant's use of the Premises shall be treated as damage to the Premises pursuant to subparagraphs (a) and (b) above.

13.

Condemnation.

(a)

If all or any portion of the Premises are taken under the power of eminent domain or sold under the threat of that power (all of which are called "Condemnation"), this Lease shall terminate as to the part taken or sold on the date the condemning authority takes title or possession, whichever occurs first. If more than 25% of the floor area of the Building or 25% of Premises are taken, either Landlord or Tenant may terminate this Lease as of the date the condemning authority takes title or possession by delivering written notice to the other within ten (10) days after receipt of written notice of such taking (or in the absence of such notice, within ten (10) days after the condemning authority takes title or possession). If neither Landlord nor Tenant terminates this Lease, this Lease shall remain in effect as to the portion of the Premises not taken, except that the Rent shall be equitably reduced in proportion to the reduction in the floor area of the improvement taken.

(b)

Any Condemnation award or payment shall be distributed in the following order: (i) first, to any mortgagee encumbering the Premises, the amount of its interest in the Premises; (ii) second, to Tenant, for moving expenses or relocation costs, cost of unamortized improvements made to the Premises, and the amount of any award specifically designated for loss or damage to Tenant's fixtures or removable personal property; and (iii) third, to Landlord, the remainder of such award, whether as compensation for reduction in the value of the leasehold, the taking of the fee, or otherwise.

(c)

If this Lease is not terminated, Landlord shall repair any damage to the Premises caused by the Condemnation, except that Landlord shall not be obligated to repair any damage for which Tenant has been reimbursed by the condemning authority. If the severance damages received by Landlord are not sufficient to pay for such repair, Landlord shall have the right to either terminate this Lease or make such repair at Landlord's expense.

14.

Hazardous Materials. The following terms shall have the meanings ascribed to them under this Paragraph:

(a)

"Hazardous Materials" shall mean any chemical, substance, material or combination thereof which is or may be hazardous to human health or safety or to the environment due to its radioactivity, ignitability, infectiousness or other harmful or potentially harmful properties or effects, including petroleum and petroleum products, asbestos, radon, polychlorinated biphenyls ("PCBs") and all of those chemicals, substances, materials or combinations thereof that are listed, defined or regulated in any manner by any Environmental Law (defined below).

7

 

(b)

"Environmental Cleanup Work" shall mean any cleanup, remediation, removal, construction, alteration, demolition, renovation or installation that is required in connection with Hazardous Materials installed, used, stored, handled or located on the Premises or disposed of from the Premises in order to comply with any Environmental Law.

(c)

"Environmental Law" shall mean any federal, state or local environmental, health and/or safety-related law, and any related decision of the courts, ordinance, rule, regulation, code, order, directive, guideline, permit or permit condition.

Tenant agrees not to store any Hazardous Materials on the Premises and agrees not to release or discard any Hazardous Materials introduced onto the Premises by it; provided, however, Tenant may store, handle and use the following chemicals, substances or materials if they are used, stored, handled and disposed of in material compliance with Environmental Laws then in effect: (i) chemicals, substances or materials routinely used in office areas or in Tenant's business operations; and (ii) janitorial supplies, cleaning fluids or other chemicals, substances or materials reasonably necessary for the day-to-day operation or maintenance of the Premises by Tenant. Notwithstanding the foregoing, Landlord acknowledges that Tenant intends to use the Premises for the purposes of storing and selling appliance parts and related equipment and such use shall be permitted under this Section.

If Tenant knows, or has reasonable cause to believe, that any Hazardous Materials has come to be located in, on, under or about the Premises, other than as previously consented to by Landlord, Tenant shall immediately give Landlord written notice thereof, together with a copy of any statement, report, notice, registration, application, permit, business plan, license, claim, action, or proceeding given to, or received from, any governmental authority or private party concerning the presence, spill, release, discharge of, or exposure to, such Hazardous Materials.

Notwithstanding any other provision of this Lease, Tenant shall and hereby does agree to indemnify, protect, defend and hold harmless Landlord and its partners, directors, officers, employees, shareholders, agents, contractors and each of their respective successors and assigns from and against any and all costs, claims, judgments, damages, penalties, fines, taxes, costs, liabilities, losses and expenses arising at any time during or after the term of this Lease as a result of or in connection with the presence of any Hazardous Materials on the Premises which were introduced onto the Premises by Tenant.

Landlord hereby represents and warrants the following to Tenant:

(a)

The Premises have not been used for the disposal of refuse or waste, or for the generation, processing, manufacture, storage, handling, treatment, release, discharge or disposal of any Hazardous Materials.

(b)

The Premises are in compliance with all Environmental Laws.

(c)

No (i) asbestos-containing materials, (ii) machinery, equipment or fixtures containing PCBs, (iii) storage tanks for gasoline or any other substance or (iv) urea formaldehyde foam insulation has been installed, used, stored, handled or located on, under or about the Premises.

8

 

(d)

Landlord shall comply with, and shall pay all costs incurred in complying with, any Environmental Law in effect on the Commencement Date and the environmental state, condition and quality of the Premises, including the performance of and payment for any Environmental Cleanup Work and the preparation of any closure or other required plans.

Notwithstanding any other provision of this Lease, Landlord shall and hereby does agree to indemnify, protect, defend and hold harmless Tenant and its partners, directors, officers, employees, shareholders, agents, contractors and each of their respective successors and assigns from and against any and all claims, judgments, damages, penalties, fines, taxes, costs, liabilities, losses and expenses (including reasonable attorneys' fees) arising at any time during or after the term of this Lease as a result of or in connection with the presence of Hazardous Materials on, under or about the Premises at the Commencement Date of this Lease or which are not introduced onto the Premises by Tenant.

15.

Notices. Whenever in this Lease it shall be required or permitted that notice or demand be given or served by either party to this Lease, such notice or demand shall be given or served in writing and sent to Landlord and Tenant at the addresses provided by the parties to each other. All such notices shall be sent by (i) certified or registered mail, return receipt requested, and shall be effective three (3) days after the date of mailing; (ii) Federal Express or similar overnight courier and shall be effective one (1) day after delivery to Federal Express or similar overnight courier; (iii) facsimile or electronic mail transmission and shall be effective on the date of transmission; or (iv) personal service and shall be effective on the same day as service. Any such address may be changed from time to time by either party serving notices as provided above.

16.

Quiet Enjoyment. Landlord represents and warrants to Tenant that Landlord is solely vested with fee simple title to the Premises with full right and lawful authority to lease the Premises to Tenant pursuant to the terms hereof. Landlord covenants with Tenant to keep Tenant in quite enjoyment and possession of the Premises without disturbance from Landlord or any party claiming by, through, or under Landlord during the term of this Lease provided Tenant is not in default under this Lease beyond any applicable cure period.

17.

Alterations and Trade Fixtures. Tenant shall have the right to make interior alterations to the Premises of a non-structural nature without Landlord's consent provided Tenant gives Landlord prior written notice of any material alterations and Tenant complies with all statutes, ordinances, codes, regulations, restrictive covenants, easements and other laws or legal requirements applicable to or affecting the Premises in connection therewith. Tenant may make structural changes only with Landlord's prior written consent.

Tenant shall have the right to remove any alterations, additions or improvements made by Tenant to the Premises and restore the Premises to the condition existing as of the Commencement Date, reasonable wear and tear, or casualty excepted. In the event Tenant elects not to remove its improvements they shall become the property of the Landlord at the expiration of the Lease term. Tenant shall have the right to remove its personal property, signs, trade fixtures, furnishings, telecommunications systems and all related equipment and components, data systems and all related equipment and components, network devices and all related equipment and components, machinery and other equipment used in the Premises and furnished by Tenant, except Tenant shall not be required to remove its telecommunications wiring or cabling.

Tenant retains the right to depreciation deductions of all such alterations, additions or improvements made at Tenant's expense.

9

 

18.

Mechanic’s Liens. Tenant shall keep the Premises free from any liens arising out of any work performed, material furnished or obligation incurred by or for Tenant or any person or entity claiming through or under Tenant. In the event that Tenant shall not, within thirty (30) days following the imposition of any such lien, cause the same to be released of record by payment or posting of a bond, Landlord shall have the right, but not the obligation, to cause such lien to be released by such means as Landlord deems reasonably proper, including payment of the claim giving rise to such lien. All such reasonable sums paid and all reasonable expenses incurred by Landlord in connection therewith shall be due and payable to Landlord by Tenant within thirty

(30) days of receipt of invoice, along with appropriate back-up documentation.

19.

Landlord’s Right of Entry. Tenant agrees to permit Landlord, or its agents or representatives, to enter into and upon any part of the Premises upon the giving of three (3) days prior written notice to Tenant (except for an emergency, in which event such prior notice to Tenant shall not be required) and at all reasonable times to inspect the same, clean, make repairs, alterations or additions thereto.

20.

Surrender of Premises. Upon the expiration or termination of this Lease, Tenant shall, at Tenant's expense, (i) remove Tenant's furniture and personal property, and (ii) quit and deliver up the Premises peaceably and quietly and otherwise in its "as is with all faults" condition. Any property left in the Premises after the expiration or termination of this Lease including, without limitation, generators, telephone and data wiring, shall be deemed to have been abandoned and the property of Landlord to dispose of as Landlord deems expedient.

21.

Holding Over. Should Tenant continue to occupy the Premises after expiration of the Term without the express written consent of Landlord, Tenant shall become a tenant at sufferance only, at a rental rate equal to one hundred ten percent (110%) of the Base Rent in effect upon the date of such expiration and otherwise upon the terms and conditions herein specified. Acceptance by Landlord of Rent after such expiration shall not constitute a consent to holdover hereunder or result in a renewal.

22.

Subordination. At the request of Landlord made in writing, Tenant will subordinate this Lease to all ground or underlying leases and to all mortgages and deeds of trust which may now or hereafter affect the Premises of which the Premises form a part, and to all renewals, modifications, consolidations, replacements and extensions thereof, provided that Tenant's right to quiet enjoyment and other rights under this Lease shall not be disturbed. Landlord shall provide and obtain for Tenant a subordination, non-disturbance and attornment agreement from the holder of any ground or underlying lease, mortgage or deed of trust whether affecting the Premises as of the Commencement Date or affecting the Premises after the Commencement Date of this Lease. Tenant shall from time to time upon request from Landlord execute and deliver any documents or instruments that may be reasonably required to effectuate such subordination, subject to review by Tenant's legal counsel.

10

 

23.

Attornment. In the event the Premises are sold or transferred due to any foreclosure sale or sales, judicial proceedings, or voluntary conveyance in lieu of such foreclosure, or in the event the Premises are transferred by any mortgagee in a sale, exchange, or otherwise, this Lease shall continue in full force and effect, and Tenant agrees, upon request, to attorn to and acknowledge the foreclosure purchaser or purchasers at such sale, or other party succeeding to the interest of Landlord, as Landlord hereunder. This Lease will, upon request of any person owning or succeeding to the interest of Landlord, automatically become a direct lease between said owner or successor and Tenant, without change in the terms or the provisions of this Lease. Upon request by said owner or successor in interest, Tenant shall execute and deliver an instrument or instruments confirming such attornment.

If the successor Landlord requests such attornment, then so long as Tenant shall faithfully discharge the obligations on its part to be kept and performed under the terms of this Lease, Tenant's tenancy will not be disturbed nor this Lease affected by any default under any mortgage. Tenant agrees that this Lease shall remain in full force and effect even though default in the mortgage may occur.

24.

Estoppel Certificates. Tenant agrees, from time to time, upon not less than thirty (30) days prior written request by Landlord, to deliver to Landlord a statement in writing certifying (a) that this Lease is unmodified and in full force and effect (or if there have been modifications that the same is in full force and effect as modified and identifying the modifications), (b) the date to which Base Rent and other charges have been paid, (c) the current Base Rent, (d) the date on which the Term commenced and ends, and the periods, if any, for which such Tenant has options to extend the Term, (e) that Tenant has accepted the Premises and is in possession, (f) that, so far as the person making the certification knows, Landlord is not in default under any provision of this Lease and, if Landlord is in default, specifying each such default of which the person making the certification may have actual knowledge, without inquiry, and (g) including such other information as the prospective purchaser, mortgagee or assignee may reasonably require.

25.

Signs. Tenant shall have the right to install in compliance with all applicable laws, regulations, ordinances and codes, signage on the exterior of the Building and/or on any monument sign containing Tenant's name, logo, or other pertinent business information.

26.

General Conditions.

(a)

Time of Essence. Time is of the essence of each provision of this Lease.

(b)

Consent of Parties. Whenever consent or approval of either party is required, that party shall not unreasonably withhold or delay such consent or approval.

(c)

Corporate Authority. Tenant and Landlord each warrant and represent that the party signing this Lease on behalf of each has authority to enter into this Lease and to bind Tenant and Landlord, respectively, to the terms, covenants and conditions contained herein. Each party shall deliver to the other, upon request, all documents reasonably requested by the other evidencing such authority, including a copy of all corporate resolutions, consents or minutes reflecting the authority of persons or parties to enter into agreements on behalf of such party.

11

 

(d)

Successors. This Lease shall be binding upon and inure to the benefit of the parties and their successors and/or assigns.

(e)

Real Estate Brokers; Finders. Each party represents that it has not had dealings with any real estate broker, finder or other person with respect to this Lease in any manner. Each party shall hold harmless the other party from all damages resulting from any claims that may be asserted against the other party by any broker, finder or other person with whom the indemnifying party has or purportedly has dealt.

(f)

Interpretation of Lease. This Lease shall be construed and interpreted in accordance with the laws of the state in which the Premises is located, without giving effect to the principles of conflicts of laws thereof.

(g)

Integrated Agreement; Modification. This Lease contains all the agreements of the parties and cannot be amended or modified except by written agreement.

(h)

Severability. The unenforceability, invalidity or illegality of any provision shall not render the other provisions unenforceable, invalid or illegal.

(i)

Attorneys’ Fees. In the event either party hereto initiates litigation or hires legal counsel to enforce or protect its rights under this Lease (including its rights of arbitration), the prevailing party shall be entitled to recover from the unsuccessful party, in addition to any other damages or relief awarded or obtained, all court costs, arbitration costs and reasonable fees (including attorneys' fees) in connection with such arbitration, litigation or action by legal counsel.

(j)

Recording. Either Tenant or Landlord may record a memorandum of the basic

terms of this Lease, including Tenant's purchase option.

(k)

Counterparts/Facsimile or Electronic Signature. This Lease may be executed simultaneously in two or more counterparts each of which shall be deemed an original, but all of which shall constitute one and the same Lease. Landlord and Tenant agree that the delivery of an executed copy of this Lease by facsimile or electronic mail shall be legal and binding and shall have the same full force and effect as if an original executed copy of this Lease had been delivered.

[SIGNATURES APPEAR ON NEXT PAGE]

12

 

IN WITNESS WHEREOF, the respective parties hereto have executed this Lease or caused this Lease to be executed by their duly authorized representatives the day and year set forth in Section 1.

			
	LANDLORD:

	 
	TENANT:

	 
	 
	 

	 
	 
	 

	Future Property Limited

	 
	Wewards, Inc.,

	 
	 
	a Nevada corporation

	 
	 
	 

	/s/ Haichao Di

	 
	/s/ Lei Pei

	 
	 
	 

	By: Haichao Di

	 
	By: Lei Pei

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]